[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 183
1. Novosel T, Ritter HE, Gupta M, Harvey A, Mitchell J, Berber E, Siperstein A, Milas M: Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas. Surgery; 2009 Dec;146(6):1081-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Circulating thyroid cancer cells detected by peripheral blood thyroid-stimulating hormone receptor (TSHR) mRNA have demonstrated usefulness for thyroid cancer diagnosis and long-term surveillance.
  • METHODS: We compared clinical characteristics of 37 patients with papillary thyroid microcarcinomas (PTMC; tumor size </=1 cm) having undetectable (-) versus detectable (+)TSHR mRNA.
  • RESULTS: 59 Of the PTMC patients, 59% had (+)TSHR mRNA levels, similar to those with tumors >1 cm (72%; P = NS) and distinctly higher than false (+) rates in benign goiters (15%; P < .001).
  • Mean tumor size (5 mm) and multifocality rates (45%) were similar in both mRNA groups.
  • [MeSH-major] Carcinoma, Papillary / blood. Carcinoma, Papillary / secondary. Neoplastic Cells, Circulating / pathology. Thyroid Neoplasms / blood. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis / genetics. Lymphatic Metastasis / pathology. Male. Middle Aged. Prospective Studies. RNA, Messenger / blood. RNA, Messenger / genetics. RNA, Neoplasm / blood. RNA, Neoplasm / genetics. Receptors, Thyrotropin / genetics. Young Adult


2. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Whether GCC represents a morphological variant of classical appendiceal carcinoid or a mucin-producing adenocarcinoma is still conjectural.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] World J Surg Oncol. 2005 Jun 20;3:36 [15967038.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38 [16253897.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Histopathology. 1992 Apr;20(4):345-9 [1577412.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):370-6 [16485156.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Ann Anat Pathol (Paris). 1969 Oct-Dec;14(4):393-406 [5378353.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):271-6 [15551743.001]
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


3. Woźniak E, Klencki M, Popowicz B, Sporny S, Słowińska-Klencka D: The recurrent goitre unusually located near the hyoid bone. Endokrynol Pol; 2010 Sep-Oct;61(5):448-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Recurrent goitre is a significant clinical problem among patients who have been operated due to benign lesions.
  • The aim of this study was to analyze if this unusual localization of recurrence is related to any significant differences in the clinical course, and if it significantly increases the risk of thyroid neoplasm.
  • The analysis included the period from the operation to the lesion-revealing US, the lesion's volume, the presence of ultrasound features of malignancy, the volume of residual thyroid tissue in the thyroid bed, the changes in volumes of examined structures, and the outcomes of cytological examinations.
  • CONCLUSIONS: Focal lesions near the hyoid bone, revealed in patients operated previously for benign goitre, are not related to increased risk of thyroid neoplasm, and their enlargement does not imply their malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21049456.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


Advertisement
4. Cunningham JL, Grimelius L, Sundin A, Agarwal S, Janson ET: Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol; 2007;46(6):747-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.
  • In some patients, however, tumour progression is more rapid and there is a need to identify them at an early stage.
  • Eighty-one patients with this tumour were included in the study; all had metastases and their survival range was 1-223 months.
  • For 57 patients whose tumour material was available, the Ki67 and apoptotic indices were calculated for ten randomly selected tumour areas and 'hot spots'.
  • One of the histopathological growth patterns-the solid (non-organoid) cell pattern-was correlated to shorter survival in both primary tumours and metastases, when compared with the organoid growth patterns (hazard ratio 2.9 and 2.3, p</=0.01).
  • Ki67 index >/=1%, in both primary tumour and metastases, identified patients at increased risk of shorter survival (hazard ratio 5.4 and 2.5, p</=0.01).
  • This study also showed that Ki67 index <2% cannot, as previously suggested, be used to indicate a benign progression for this tumour category.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoid Tumor / physiopathology. Cecal Neoplasms / physiopathology. Ileal Neoplasms / physiopathology. Ki-67 Antigen / analysis. Serotonin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Disease Progression. Female. Health Status Indicators. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653896.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 333DO1RDJY / Serotonin
  •  go-up   go-down


5. Hutchinson CB, Canlas K, Evans JA, Obando JV, Waugh M: Endoscopic ultrasound-guided fine needle aspiration biopsy of the intrapancreatic accessory spleen: a report of 2 cases. Acta Cytol; 2010 May-Jun;54(3):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intrapancreatic accessory spleen (IPAS) can pose a challenge in the diagnostic workup by mimicking a pancreatic neoplasm.
  • Reports of IPAS identified by endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) are scant in the literature, and increased recognition of this benign entity may reduce misdiagnosis and unnecessary surgical intervention.
  • In both cases, the cytomorphologic appearance of smears and cell blocks demonstrated aggregates of benign splenic tissue characteristic of both white and red pulp.
  • One cell block demonstrated benign splenic and pancreatic parenchyma immediately adjacent to one another without an apparent intervening capsule.
  • Definitive tissue diagnosis in these 2 cases avoided not only unnecessary surgical intervention but also the need for consideration of a "watch and wait" strategy with further imaging and possible additional biopsy attempts.
  • [MeSH-major] Choristoma / diagnosis. Pancreatic Diseases / diagnosis. Spleen
  • [MeSH-minor] Adenocarcinoma / diagnosis. Antigens, CD / metabolism. Biomarkers / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Endocrine Gland Neoplasms / diagnosis. Endosonography. Female. Humans. Male. Middle Aged. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518423.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers
  •  go-up   go-down


6. Bhandari T, Dizon DS, Taneja C, Gass J, Masko GD, Strenger R: Clinical characteristics of women presenting with skin-only recurrence of breast cancer. Am J Surg; 2007 Oct;194(4):494-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, locoregional recurrence may have different presentations, some of which may represent a more benign course.
  • Histologic and treatment data as it related to their primary diagnosis and demographic data were obtained by chart review.
  • The median age at original diagnosis was 61 years (range 33-94 years).
  • Ten patients went on to receive endocrine therapy, 6 received chemotherapy, and 2 were observed.
  • CONCLUSIONS: Patients experiencing a chest wall recurrence may have a benign course suggesting this may be an indolent presentation of local regional recurrence.
  • [MeSH-major] Breast Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Skin Neoplasms / therapy. Thoracic Wall
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Thoracic Neoplasms

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826063.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Sakurai K, Enomoto K, Amano S: [Long-term results of surgical therapy for phyllodes tumor of the breast]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2784-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results of surgical therapy for phyllodes tumor of the breast].
  • We report that the long-term results of surgical therapy for phyllodes tumor of the breast.
  • The patients with local recurrence were diagnosed the benign phyllodes tumor of the breast at the first operation.
  • If the pathological diagnosis was benign phyllodes tumor and surgical margin was negative at the first operation, it is necessary to follow up the patients, because there is a risk of local and distant metastasis.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Mastectomy / methods. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Jabiev AA, Ikeda MH, Reis IM, Solorzano CC, Lew JI: Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules. Ann Surg Oncol; 2009 Nov;16(11):3140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were subdivided into two groups based on final pathology results: patients with DTC(n=61) and those with benign disease (BD) (n=54).
  • [MeSH-major] Carcinoma, Papillary, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography. Thyroid Nodule / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S301 [20839063.001]
  • [CommentIn] Ann Surg Oncol. 2011 Jan;18(1):292 [20490696.001]
  • (PMID = 19655201.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M: Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol; 2008 May;19(5):903-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.
  • BACKGROUND: Non-functioning pancreatic endocrine tumours (NF-PETs) are an aggressive gastroenteropancreatic neoplasm.
  • The present study assessed survival, value of World Health Organisation (WHO) classification and prognostic utility of clinicopathological parameters at diagnosis.
  • RESULTS: There were 25 (14%) benign lesions, 38 (21%) neoplasms of uncertain behaviour, 100 well-differentiated carcinomas (56%) and 17 poorly differentiated carcinomas (9%).

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209014.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


10. Krysiak R, Okopień B: [Parathyroid carcinoma]. Pol Merkur Lekarski; 2007 Aug;23(134):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parathyroid carcinoma is a rare endocrine tumour accounting for only about one of every hundred cases of primary hyperparathyroidism.
  • Most patients with parathyroid carcinoma suffer from symptoms related to marked hypercalcemia; the incidence of associated renal, bone, gastrointestinal, neuromuscular and psychological symptoms is much more frequent than in those with benign parathyroid adenomas.
  • The treatment of parathyroid malignancy is predominantly surgical, comprising an initial en bloc resection of the tumour and adjacent neck structures.
  • The aim of this paper is to summarise the present state of knowledge on the aetiology, clinical presentation, diagnosis and treatment of parathyroid carcinoma.
  • [MeSH-major] Parathyroid Neoplasms / diagnosis. Parathyroid Neoplasms / therapy
  • [MeSH-minor] Calcium / blood. Humans. Hypercalcemia / drug therapy. Hypercalcemia / etiology. Hypercalcemia / physiopathology. Hyperparathyroidism / diagnosis. Hyperparathyroidism / etiology. Hyperparathyroidism / physiopathology. Hyperparathyroidism, Primary / etiology. Multiple Endocrine Neoplasia / complications. Neoplasm Metastasis. Parathyroid Glands / pathology. Parathyroid Glands / secretion. Parathyroid Glands / surgery. Parathyroid Hormone / blood. Parathyroidectomy. Prognosis. Radionuclide Imaging. Rare Diseases. Risk Factors

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18044348.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Parathyroid Hormone; SY7Q814VUP / Calcium
  • [Number-of-references] 39
  •  go-up   go-down


11. Basturk O, Coban I, Adsay NV: Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med; 2009 Mar;133(3):423-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications.
  • OBJECTIVE: To provide an overview of the current concepts in classification, differential diagnosis, and clinical/biologic behavior of pancreatic cystic tumors.
  • CONCLUSIONS: In contrast to solid tumors, most of which are invasive ductal adenocarcinomas with dismal prognosis, cystic lesions of the pancreas are often either benign or low-grade indolent neoplasia.
  • However, those that are mucinous, namely, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, constitute an important category because they have well-established malignant potential, representing an adenoma-carcinoma sequence.
  • Only rare nonmucinous cystic tumors that occur as a result of degenerative/necrotic changes in otherwise solid neoplasia, such as cystic ductal adenocarcinomas, cystic pancreatic endocrine neoplasia, and solid-pseudopapillary neoplasm, are also malignant and have variable degrees of aggressiveness.
  • [MeSH-major] Pancreatic Cyst / diagnosis. Pancreatic Cyst / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Pancreatic Pseudocyst / diagnosis. Pancreatic Pseudocyst / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260748.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 204
  •  go-up   go-down


12. Foukakis T, Gusnanto A, Au AY, Höög A, Lui WO, Larsson C, Wallin G, Zedenius J: A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer; 2007 Jun;14(2):381-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis of follicular thyroid carcinoma (FTC) in the absence of metastasis can only be established postoperatively.
  • Moreover, high-risk FTCs are often not identifiable at the time of diagnosis.
  • The metastatic potential could be predicted in all four cases with apparently benign or minimally invasive (MI) disease at the time of diagnosis, but poor long-term outcome.
  • In addition, a second model was produced by implementing two genes (TERT and TFF3), which was able to distinguish adenomas from de facto carcinomas.
  • When this model was tested in an independent series of atypical adenomas (AFTA) and MI-FTCs, 16 out of 17 AFTAs were classified as 'benign', while MI-FTCs with vascular invasion (sometimes referred to as 'moderately invasive') and/or large tumor size tended to classify in the 'malignant' group.
  • The reported models can be the foundation for the development of reliable preoperative diagnostic and prognostic tests that can guide the therapeutic approach of follicular thyroid neoplasms with indeterminate cytology.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Gene Expression. Genes, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639052.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


13. Milas M, Shin J, Gupta M, Novosel T, Nasr C, Brainard J, Mitchell J, Berber E, Siperstein A: Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg; 2010 Oct;252(4):643-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In initial studies, the detection of circulating DTC cells by thyrotropin receptor (TSHR) mRNA measurement distinguished benign from malignant thyroid diseases.
  • METHODS: TSHR mRNA was measured by quantitative RT-PCR from blood drawn perioperatively in patients undergoing thyroid surgery (n = 526), postoperatively in patients undergoing DTC follow-up (n = 418) and in patients monitored for known benign disease (n = 151).
  • The reference range and applications for TSHR mRNA were previously defined from 663 samples from patients with normal, benign, and malignant thyroid disease.
  • RESULTS: In patients with follicular neoplasms or suspicious cytology, preoperative TSHR mRNA >1 ng/μg had 96% predictive value for DTC, whereas 95% of patients with undetectable mRNA and benign thyroid sonography had benign disease.
  • It is particularly useful in guiding appropriate initial surgery for follicular neoplasms.
  • [MeSH-major] Biomarkers / blood. RNA, Messenger / blood. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Algorithms. Autoantibodies / blood. Follow-Up Studies. Humans. Neoplasm Recurrence, Local / blood. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Thyroglobulin / immunology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881771.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


14. Kaltsas G, Androulakis II, de Herder WW, Grossman AB: Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer; 2010 Sep;17(3):R173-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumours may be either benign or malignant tumours, and have the ability to synthesise and secrete biologically active substances characteristic of the cell of origin that can cause distinct clinical syndromes.
  • The term 'paraneoplastic syndromes' (PNSs) is used to denote syndromes secondary to substances secreted from tumours not related to their specific organ or tissue of origin and/or production of autoantibodies against tumour cells; such syndromes are mainly associated with hormonal and neurological symptoms.
  • Appreciation of the presence of such syndromes is important as clinical presentation, if not identified, may delay the diagnosis of the underlying neoplasia.
  • Conversely, early recognition can allow for more rapid diagnosis, particularly as the coexistence of a neoplasm with a clinical or biochemical marker offers an additional determinant of tumour status/progression.
  • Their diagnosis involves a multidisciplinary approach, and detailed endocrinological, neurological, radiological and histological studies are required.
  • Correct diagnosis is essential as the treatment of choice will be different for each disorder, particularly in the case of malignant tumours; it is therefore important to develop appropriate means to correctly identify and localise these tumours.
  • Disease-specific medical therapies are mandatory in order to prevent recurrence and/or further tumour growth.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530594.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


15. Ge C, Luo X, Chen X, Guo K: Enucleation of pancreatic cystadenomas. J Gastrointest Surg; 2010 Jan;14(1):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) the benign nature of the tumors was ascertained preoperatively and intraoperatively, (2) small tumors or larger tumors no more than 6 cm in diameter growing outwardly with small tumor beds, and (3) the main pancreatic duct was not in jeopardy of damage by enucleation.
  • The patients' demographics, tumor features, morbidity, and follow-up results were retrospectively reviewed and analyzed.
  • RESULTS: Among 11 cases, three were serous cystadenomas and eight were mucinous cystadenomas; the average size of the neoplasms was 4.8 cm (ranging from 3 to 6 cm).
  • All cases were followed up from 23 to 67 months, which revealed no neoplasm recurrence or new onset of diabetes mellitus; one patient developed a pseudocyst in the body 30 months after enucleation.
  • CONCLUSIONS: It is safe and effective to perform enucleation for well-selected benign pancreatic cystadenomas even if the tumor size is as large as 6 cm, and the endocrine or exocrine function of the pancreas is maintained as much as possible.
  • [MeSH-major] Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1987 Apr;205(4):393-8 [3566376.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):896-903 [9637553.001]
  • [Cites] J Intern Med. 1995 Sep;238(3):269-80 [7673858.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(2):167-70 [17384908.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1681-6 [14571816.001]
  • [Cites] Baillieres Clin Gastroenterol. 1996 Dec;10(4):645-71 [9113316.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):327-31 [16504877.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Br J Surg. 2006 Mar;93(3):264-75 [16498592.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Jan;24(1):121-4 [10679598.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):132-9 [1546898.001]
  • [Cites] Ann Surg. 2004 May;239(5):651-7; discussion 657-9 [15082969.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):890-7 [14592663.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1254-9 [17583892.001]
  • [Cites] Am Surg. 2004 Feb;70(2):106-12; discussion 113 [15011911.001]
  • [Cites] J Gastrointest Surg. 2007 Jun;11(6):726-9 [17726774.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • (PMID = 19779948.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Ma XX, Zhang SL, Gao S, Lu JM, Dong F: [Expressions of aromatase protein and sex hormone receptor in endometrial lesions]. Zhonghua Fu Chan Ke Za Zhi; 2006 Jun;41(6):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the expression of aromatase protein, estrogen receptor (ER), progesterone receptor (PR) and nuclear antigen associated with cell proliferation Ki67 in endometrial diseases and their clinical significance in diagnosis and endocrine therapy of endometrial diseases.
  • METHOD: Expressions of aromatase, ER, PR and Ki-67 were detected with immunohistochemistry technic (streptavidin-peroxidase-biotin, SP) in 148 cases including 30 of endometrial hyperplasia, 30 of atypical proliferation and 88 of endometrial adenocarcinoma as observational group and 15 cases of proliferative endometrium and 15 cases of secretory endometrium as control group.
  • RESULTS: Expression of aromatase protein and ER, PR, Ki67 in endometrial hyperplasia, atypical proliferation had no significant difference comparing with the proliferative endometrium group (P > 0.05).
  • In endometrial adenocarcinoma, the expression of aromatase protein increased obviously (64%, 56/88), which was higher than in benign diseases [atypical proliferation group was 23% (7/30), endometrial hyperplasia group was 13% (4/30)] and control group significantly (P < 0.01).
  • The positive expression of ER, PR in endometrial adenocarcinoma decreased [22% (19/88), 19% (17/88)], and Ki67 increased (41%, 36/88) and there was a significant difference compared with control group (P < 0.01).
  • Aromatase was not consistent with ER, PR and Ki67 in endometrial adenocarcinoma.
  • CONCLUSION: Aromatase protein is related to the incidence of endometrial adenocarcinoma, and the expression of proteins (aromatase, ER, PR and Ki67) provides theoretical basis for understanding biological behavior of endometrial adenocarcinoma.
  • [MeSH-major] Aromatase / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Receptors, Steroid / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Biomarkers / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Neoplasm Staging. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831363.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Receptors, Steroid; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


17. Molinié V, Ruffion A, Allory Y, Leroy X, Cochand Priollet B, Paraf F, de la Taille A: [Is tumour grade applicable to finasteride-treated prostate cancer?]. Prog Urol; 2005 Jun;15(3):387-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is tumour grade applicable to finasteride-treated prostate cancer?].
  • [Transliterated title] Un grade tumoral est-il applicable au cancer de la prostate sous finastéride?
  • The treatment of prostate cancer by endocrine therapy induces histological changes of benign or malignant prostate glands.
  • Most authors appear to agree that cancers discovered by biopsy in patients treated with endocrine therapy should not be graded.
  • (1) the extent of histological changes after androgen deprivation endocrine therapy;.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] 5-alpha Reductase Inhibitors. Animals. Atrophy. Clinical Trials as Topic. Humans. Male. Neoplasm Staging. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / drug therapy. Prostatic Intraepithelial Neoplasia / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097140.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  • [Number-of-references] 33
  •  go-up   go-down


18. Alsharif M, Carlo-Demovich J, Massey C, Madory JE, Lewin D, Medina AM, Recavarren R, Houser PM, Yang J: Telecytopathology for immediate evaluation of fine-needle aspiration specimens. Cancer Cytopathol; 2010 Jun 25;118(3):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: On-site evaluation of fine-needle aspiration (FNA) specimens by a pathologist is essential to obtain adequate samples and provide a preliminary diagnosis.
  • The authors present their experience with on-site evaluation using telecytopathology.
  • A pathologist accessed the real-time images on a computer and interpreted them while communicating with on-site operators over the telephone.
  • Sample adequacy and accuracy of preliminary diagnosis were compared with those obtained by regular on-site evaluation.
  • RESULTS: A total of 429 telecytopathology cases and 363 conventional on-site cases were compared.
  • Preliminary diagnoses of unsatisfactory, adequate (defer), negative/benign, atypical, neoplasm, suspicious, and positive for malignancy were 6.3%, 13.5%, 14.9%, 17.9%, 7.2%, 8.6%, and 31.5% for telecytopathology and 3.9%, 30.6%, 21.5%, 9.6%, 5.0%, 5.2%, and 24.2% for conventional cases.
  • Difficulty was encountered in some cases in distinguishing pancreatic endocrine neoplasm from lymphoid proliferations, and low grade pancreatic tumors from chronic pancreatitis via telecytopathology.
  • CONCLUSIONS: On-site evaluation of FNA specimens via telecytopathology assures sample adequacy and accurate preliminary diagnosis compared with the conventional method.
  • It allows pathologists to use their time more efficiently and makes on-site evaluations at remote locations possible.
  • [MeSH-major] Biopsy, Fine-Needle. Neoplasms / diagnosis. Telepathology / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Cancer Society.
  • [CommentIn] Cancer Cytopathol. 2010 Jun 25;118(3):115-8 [20544703.001]
  • (PMID = 20544707.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Pinchot SN, Al-Wagih H, Schaefer S, Sippel R, Chen H: Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg; 2009 Jul;144(7):649-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger.
  • The FNAB results were reported as nondiagnostic, benign, inconclusive (follicular neoplasm), or malignant, whereas the final surgical pathologic data were reported as benign or malignant.
  • Preoperative cytologic testing of the mass was performed on 97 patients, and the results read as benign for 52, inconclusive for 23, nondiagnostic for 11, and malignant for 11.
  • In lesions 4 cm or larger, 26 of 52 FNAB results reported as benign (50.0%) turned out to be either neoplastic (22) or malignant (4) on final pathologic analysis.
  • Among patients with nondiagnostic FNAB results, the risk of malignant neoplasms was 27.3%.
  • CONCLUSIONS: In patients with thyroid nodules 4 cm or larger, the FNAB results are highly inaccurate, misclassifying half of all patients with reportedly benign lesions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2006 Apr;13(2):89-98 [16735982.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):859-63 [16614881.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Oct;65(4):500-5 [16984243.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):714-20 [17968160.001]
  • [Cites] Surgery. 2007 Dec;142(6):837-44; discussion 844.e1-3 [18063065.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Mar;93(3):809-14 [18160464.001]
  • [Cites] Surgery. 2008 Jun;143(6):835-6 [18549905.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Jul;139(1):27-31 [18585557.001]
  • [Cites] Ann Surg. 2008 Aug;248(2):343-4; author reply 344 [18650649.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):917-21 [10828810.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1764-71 [15496625.001]
  • [Cites] Surgery. 1988 Dec;104(6):947-53 [3194846.001]
  • [Cites] Acta Endocrinol (Copenh). 1989 Aug;121(2):197-202 [2773619.001]
  • [Cites] Radiology. 1991 Dec;181(3):683-7 [1947082.001]
  • [Cites] J Surg Oncol. 1992 Aug;50(4):247-50 [1640709.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):282-9 [8420446.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2680-5 [8402490.001]
  • [Cites] Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8 [8256208.001]
  • [Cites] Arch Intern Med. 1994 Aug 22;154(16):1838-40 [8053752.001]
  • [Cites] Surgery. 1995 Dec;118(6):996-1003; discussion 1003-4 [7491545.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):913-6 [9379692.001]
  • [Cites] J Clin Endocrinol Metab. 1955 Oct;15(10):1270-80 [13263417.001]
  • [Cites] Thyroid. 2005 Jul;15(7):708-17 [16053388.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7 [16835280.001]
  • (PMID = 19620545.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090217-08; United States / NCI NIH HHS / CA / T32 CA090217-09; United States / NCI NIH HHS / CA / T32 CA090217-10; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / CA090217-10; United States / NCI NIH HHS / CA / T32 CA090217-08; United States / NCI NIH HHS / CA / CA090217-09
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS215984; NLM/ PMC2910711
  •  go-up   go-down


20. Fritzsche S, Kenzelmann M, Hoffmann MJ, Müller M, Engers R, Gröne HJ, Schulz WA: Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer; 2006 Sep;13(3):839-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We found both genes modestly down-regulated by microarray expression analysis of microdissected prostate cancers and by quantitative RT-PCR in macrodissected specimens compared with benign tissues.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Membrane Proteins / genetics. Phosphoproteins / genetics. Prostatic Neoplasms / genetics. Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA Primers. Gene Amplification. Humans. Intracellular Signaling Peptides and Proteins. Male. Oligonucleotide Array Sequence Analysis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954433.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / Proteins; 0 / RNA, Neoplasm; 0 / SPRY1 protein, human; 0 / SPRY2 protein, human
  •  go-up   go-down


21. Souissi A, Fenniche S, Benmously R, Marrak H, Ben Jannet S, Mokhtar I: [Acanthosis nigricans: epidemiologic study of 69 cases]. Tunis Med; 2008 Jan;86(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Acanthosis nigricans: étude épidémiologique de 69 cas.
  • BACKGROUND: Acanthosis nigricans is a well-defined skin disorder with a distinctive appearance and an elective topography to the flexural areas that facilitate its diagnosis.
  • All the patients presented a benign AN, comprising 51 cases of pseudo-AN, 11 cases of AN associated with endocrine diseases, 5 cases of familial AN and 2 cases of AN associated with an auto-immune disease.
  • AN constitutes a double cutaneous marker, being able to reveal either an hyperinsulinemia constituting a cardiovascular risk factor or an ignored subjacent neoplasm engaging the vital prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Autoimmune Diseases / epidemiology. Child. Child, Preschool. Endocrine System Diseases / epidemiology. Female. Humans. Male. Middle Aged. Retrospective Studies. Tunisia / epidemiology. Young Adult

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472702.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


22. Kebebew E, Peng M, Reiff E, McMillan A: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer; 2006 Jun 15;106(12):2592-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.
  • The purpose of the current study was to determine the accuracy of novel candidate diagnostic markers to distinguish benign from malignant thyroid neoplasms, and to predict the extent of disease.
  • RESULTS: The levels of ECM1, TMPRSS4, ANGPT2, and TIMP1 mRNA expression were found to be independent diagnostic markers of malignant thyroid neoplasms.
  • [MeSH-major] Biomarkers, Tumor / genetics. Genes, Neoplasm / genetics. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Angiopoietin-2 / analysis. Angiopoietin-2 / genetics. Biopsy, Fine-Needle. Data Interpretation, Statistical. Diagnosis, Differential. Ephrin-B2 / analysis. Ephrin-B2 / genetics. Extracellular Matrix Proteins / analysis. Extracellular Matrix Proteins / genetics. Humans. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Messenger / genetics. ROC Curve. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Serine Endopeptidases / analysis. Serine Endopeptidases / genetics. Thyroid Diseases / diagnosis. Thyroid Diseases / genetics. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-1 / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16688775.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Biomarkers, Tumor; 0 / ECM1 protein, human; 0 / Ephrin-B2; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / transmembrane serine protease 2, human
  •  go-up   go-down


23. Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ: BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid; 2009 Apr;19(4):347-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both of these events are implicated in carcinogenesis, tumor progression, recurrence, etc.
  • METHODS: Genomic DNA was extracted from 123 paraffin-embedded PTC tumor tissue samples and amplified for analysis of the V600E mutation in exon 15 of the BRAF gene by polymerase chain reaction.
  • XIAP expression was examined by immunohistochemical methods in 46 PTCs, 18 benign nodular goiters, and 10 Hashimoto's thyroiditis samples.
  • BRAF(V600E) was significantly correlated with younger age at diagnosis (p = 0.026), tumor size (p = 0.009), and histological variants (p = 0.024).
  • By logistic regression analysis, a significant relationship was found between tumor size and the BRAF(V600E) mutation (p = 0.03).
  • XIAP was expressed in 82.6% of PTCs, which was a higher percentage than observed in the group of benign thyroid disorders (35.7%, p < 0.001).
  • CONCLUSIONS: These data indicate that BRAF(V600E) is associated some of the aggressive clinicopathological features of PTC including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion.
  • XIAP-positive staining was more prevalent in PTCs than in the benign thyroid disorders.
  • [MeSH-major] Carcinoma, Papillary / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. X-Linked Inhibitor of Apoptosis Protein / genetics
  • [MeSH-minor] Adult. Amino Acid Substitution. Female. Goiter, Nodular / genetics. Hashimoto Disease / genetics. Humans. Male. Middle Aged. Neoplasm Invasiveness / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355825.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


24. Alasio TM, Vine A, Sanchez MA, Dardik H: Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature. Ann Diagn Pathol; 2005 Aug;9(4):234-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumor coexistent with serous microcystic adenoma: report of a case and review of the literature.
  • Serous cystadenomas of the pancreas have been classified as benign exocrine tumors.
  • There have been rare cases of malignant behavior, and in exceptional cases, coexisting neoplasms have been reported.
  • We report a case of a coexistent neuroendocrine tumor identified within a serous cystadenoma in a 78-year-old woman, which was discovered incidentally after complete resection of the tumor.
  • Given the unpredictable metastatic potential of neuroendocrine tumors of the pancreas, we advocate complete resection of all pancreatic cystic tumors, combined with careful sampling of the pathological specimen to rule out a coexistent potentially malignant neoplasm.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic adenoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084460.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Wada I, Shimizu N, Seto Y: [Treatment of neuroendocrine tumors of the digestive tract]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1606-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine tumors of the digestive tract are relatively rare and comprise benign and malignant tumors.
  • European Neuroendocrine Tumor Society(ENETS)proposed grading system and TNM classification system with disease staging for endocrine tumors of each organ which are both valid tools for prognostic stratification.
  • The only curative therapy is the complete resection of the tumor.
  • Octreotide and Pasireotide (SOM230), somatostatin analogues, are reported to have the benefit of both hormonal symptom control and tumor growth suppression.
  • [MeSH-major] Antinematodal Agents / therapeutic use. Digestive System Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Staging. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838017.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antinematodal Agents
  •  go-up   go-down


26. Montone KT, Rosen M, Siegelman ES, Fogt F, Livolsi VA: Adrenocortical neoplasms with myelolipomatous and lipomatous metaplasia: report of 3 cases. Endocr Pract; 2009 Mar;15(2):128-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical neoplasms with myelolipomatous and lipomatous metaplasia: report of 3 cases.
  • OBJECTIVE: To present pathologic and radiographic features of 3 patients with adrenocortical neoplasms-2 with uncertain malignant potential and 1 adenoma with areas of myelolipomatous and lipomatous metaplasia.
  • METHODS: We describe 3 patients who had adrenocortical neoplasms with foci of myelolipomatous and lipomatous metaplasia.
  • The lesion size averaged 6.8 cm (range, 3.9 to 11.0), and the mean gland weight was 128.8 g (range, 32.5 to 249).
  • Pathologically, 2 of the lesions were classified as adrenocortical neoplasms of uncertain malignant potential, and 1 lesion was classified as an adrenocortical adenoma.
  • All 3 lesions contained myelolipomatous foci throughout the neoplasm, and 2 of the tumors contained several pure lipomatous foci.
  • CONCLUSION: Adrenocortical neoplasms, including those associated with an uncertain malignant potential, may be associated with areas of myelolipomatous and lipomatous metaplasia.
  • Imaging studies may result in a false diagnosis of a benign adrenal myelolipoma and potential undertreatment in such patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / pathology. Lipomatosis / diagnosis. Metaplasia / diagnosis. Myelolipoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289323.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC: Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis. Endocr Relat Cancer; 2008 Mar;15(1):243-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to compare a molecular classification with the World Health Organization (WHO) histologic classification, identify genes that may be important for tumor progression, and determine whether gastrointestinal NETs (GI-NETs) differ in their molecular profile from pancreatic NETs (PNETs).
  • Hierarchical clustering of 19 PNETs revealed a 'benign' and 'malignant' cluster that corresponded well with the WHO categories of well-differentiated endocrine tumor (WDET) and well-differentiated endocrine carcinoma (WDEC) respectively.
  • Gene expression profiles reflect the current WHO classification and can distinguish benign from malignant PNETs and also PNETs from GI-NETs.
  • This suggests that molecular profiling may enhance tumor classification schemes.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310291.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; None / None / / P30 DK040561-12; United States / NIDDK NIH HHS / DK / P30 DK040561-12
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


28. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P: Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer; 2009 Dec;16(4):1251-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relationship between TSH and papillary thyroid cancer (PTC) has been analyzed in 10 178 patients submitted to fine needle aspiration of thyroid nodules with a cytology of PTC (n=497) or benign thyroid nodular disease (BTND, n=9681).
  • In 942 patients, submitted to surgery (521 from BTND and 421 from PTC), the histological diagnosis confirmed an elevated specificity (99.6%) and sensitivity (98.1%) of cytology.
  • TSH levels were significantly higher in PTC than in BTND both in the cytological and histological series and also in patients with a clinical diagnosis of multinodular goiter (MNG) and single/isolate nodule (S/I).
  • A significant age-dependent development of thyroid autonomy (TSH <0.4 microU/ml) was observed in patients with benign thyroid disease, but not in those with PTC, diagnosed both on cytology and histology.
  • [MeSH-major] Carcinoma, Papillary / blood. Thyroid Neoplasms / blood. Thyroid Nodule / blood. Thyrotropin / blood
  • [MeSH-minor] Autoantibodies / blood. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Thyroid Function Tests


29. Matyja E, Maksymowicz M, Grajkowska W, Olszewski W, Zieliński G, Bonicki W: Spindle cell oncocytoma of the adenohypophysis - a clinicopathological and ultrastructural study of two cases. Folia Neuropathol; 2010;48(3):175-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spindle cell oncocytoma (SCO) of the pituitary gland is a relatively recently established, very rare subtype of adenohypophysis tumours that was introduced as a distinct clinicopathological entity in the fourth edition of WHO classification of the central nervous system tumours (2007).
  • It is non-endocrine neoplasm of the anterior pituitary that occurs in adults and usually follows a benign clinical course, corresponding to WHO grade I.
  • The clinical and radiological features suggested non-functioning pituitary macroadenomas without evidence of invasive growth.
  • One patient presented with tumour recurrence 3 years after undergoing the previous surgical removal of tumour, which was initially misdiagnosed as schwannoma.
  • The first tumour was removed by transsphenoidal surgery and the second one by frontal craniotomy.
  • The tumour cells exhibited immunoreactivity for S-100 protein, galectin-3, vimentin and epithelial membrane antigen but they were negative for GFAP, anterior pituitary neuroendocrine markers (prolactin, growth hormone, TSH, ACTH, FSH, LH), chromogranin, synaptophysin, cytokeratin CK (AE1/AE3), smooth muscle actin, desmin, CD34 and CD68.
  • Ultrastructurally, the tumour cells were rich in mitochondria with lamellar cristae.
  • Moreover, in Case 2 some tumour cells showed a number of giant mitochondria with severely destructed internal matrix.
  • It should be considered in the differential diagnosis of various sellar-region lesions of oncocytic morphology.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925001.001).
  • [ISSN] 1509-572X
  • [Journal-full-title] Folia neuropathologica
  • [ISO-abbreviation] Folia Neuropathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


30. Blanes A, Sanchez-Carrillo JJ, Diaz-Cano SJ: Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair. J Clin Endocrinol Metab; 2006 Mar;91(3):1150-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN AND SETTING: Microdissected samples from the peripheral and internal zones of 143 pheochromocytomas from a referral hospital (95 sporadic and 48 associated with multiple endocrine neoplasia type 2A) were selected for loss of heterozygosity and single nucleotide polymorphism analyses.
  • PATIENTS, OUTCOME MEASURES, AND INTERVENTIONS: Pheochromocytomas were classified as malignant (16 sporadic tumors with distant metastases), locally invasive (30 sporadic tumors showing retroperitoneal infiltration only), and benign (all remaining tumors).
  • More genetic abnormalities involving the peripheral compartment were revealed in 34 pheochromocytomas (23.8%): 12 of 16 malignant, 10 of 30 locally invasive, and 12 of 97 benign.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / pathology. Base Pair Mismatch / genetics. DNA Repair / genetics. Gene Expression Regulation, Neoplastic. Pheochromocytoma / genetics. Pheochromocytoma / pathology
  • [MeSH-minor] Adrenal Medulla / pathology. Base Sequence. DNA Primers. DNA, Neoplasm / genetics. DNA, Satellite / genetics. Genes, p53. Humans. Loss of Heterozygosity. Multiple Endocrine Neoplasia Type 2a / genetics. Polymorphism, Single Nucleotide. Retinoblastoma Protein / genetics


31. Angeles-Angeles A: [Endocrine neoplasm of the stomach. Study of thirteen cases]. Gac Med Mex; 2005 May-Jun;141(3):207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endocrine neoplasm of the stomach. Study of thirteen cases].
  • [Transliterated title] Tumores endocrinos del estómago. Análisis de 13 casos.
  • A Thirteen patients with primary endocrine neoplasm of the stomach were studied for 20 years.
  • These two forms of neoplasm showed important differences: those associated with atrophic gastritis had hypergastrinemia, all of the multiple small tumors confined to the corpus and fundus were well differentiated carcinoids associated with intestinal metaplasia and G cell hyperplasia in antrum and ECL cell hyperplasia in corpus and fundus.
  • Tumors were clinically benign, with an excellent prognosis.
  • All patients are currently alive with no evidence of neoplasm.
  • Two patients died as a consequence of the neoplasm; all of them were moderately differentiated and in none of the cases we found evidence of endocrine hyperplasia.
  • All were positive for generic endocrine markers and were focally positive to some of the specific hormone markers.
  • [MeSH-major] Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025986.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


32. Jonkers YM, Ramaekers FC, Speel EJ: Molecular alterations during insulinoma tumorigenesis. Biochim Biophys Acta; 2007 Jun;1775(2):313-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulinomas are the most common functioning endocrine pancreatic tumors (EPTs).
  • Some tumors may harbor MEN1 gene mutations, the susceptibility gene of the multiple endocrine neoplasia type I syndrome, but most cases show wildtype MEN1.
  • Currently, no reliable clinical tests are available to differentiate benign from malignant tumors.
  • Therefore, a better understanding of the molecular processes underlying the development and progression of insulinomas is required to improve diagnosis, prognosis and therapy.
  • We describe the clinical detection, classification and treatment of these tumors, and review the multiplicity of molecular and genetic studies that investigated tumor development and progression using either primary tumors, transgenic mouse models or tumor-derived cell lines.
  • In addition, these studies will pave the way for the identification of novel targets for therapeutical intervention and more reliable markers for clinical diagnosis and prognosis.
  • [MeSH-major] Insulinoma / genetics. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Genetic Markers. Humans. Neoplasm Invasiveness. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Signal Transduction / physiology


33. Lew JI, Solorzano CC: Use of ultrasound in the management of thyroid cancer. Oncologist; 2010;15(3):253-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the late 1960s, ultrasound has become essential in the examination of the thyroid gland with the increased availability of high-frequency linear array transducers and computer-enhanced imaging capabilities of modern day portable ultrasound equipment in a clinic- or office-based setting.
  • Ultrasound has become useful in the qualitative characterization of thyroid nodules based on benign or malignant features.
  • [MeSH-major] Thyroid Neoplasms / ultrasonography. Thyroid Nodule / ultrasonography
  • [MeSH-minor] Biopsy, Needle / methods. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1364-9 [16434461.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Sep;92(9):3590-4 [17609301.001]
  • [Cites] Laryngoscope. 2008 Feb;118(2):228-31 [17989576.001]
  • [Cites] Thyroid. 2008 May;18(5):523-31 [18466077.001]
  • [Cites] Radiology. 2008 Jun;247(3):762-70 [18403624.001]
  • [Cites] Laryngoscope. 2008 Jun;118(6):991-4 [18401275.001]
  • [Cites] Thyroid. 2008 Jun;18(6):609-14 [18578609.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Jul;139(1):27-31 [18585557.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2487-92 [18622644.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jan;192(1):66-72 [19098181.001]
  • [Cites] World J Surg. 2009 Mar;33(3):434-9 [18958519.001]
  • [Cites] World J Surg. 2009 May;33(5):950-7 [19288281.001]
  • [Cites] Ann Surg Oncol. 2009 Jun;16(6):1655-9 [19319605.001]
  • [Cites] AJR Am J Roentgenol. 2009 Jul;193(1):207-13 [19542415.001]
  • [Cites] Ann Surg Oncol. 2009 Nov;16(11):3140-5 [19655201.001]
  • [Cites] Ann Intern Med. 2000 Nov 7;133(9):696-700 [11074902.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):687-91 [11856699.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Surgery. 2002 Dec;132(6):924-8; discussion 928-9 [12490837.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):31-40 [12833452.001]
  • [Cites] Surgery. 2003 Dec;134(6):946-54; discussion 954-5 [14668727.001]
  • [Cites] Am Surg. 2004 Jul;70(7):576-80; discussion 580-2 [15279178.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1764-71 [15496625.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):559-67; discussion 567-8 [7725745.001]
  • [Cites] Thyroid. 1998 Jan;8(1):15-21 [9492148.001]
  • [Cites] Thyroid. 1998 Apr;8(4):283-9 [9588492.001]
  • [Cites] Surgery. 2005 Dec;138(6):1193-200; discussion 1200-1 [16360408.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):60-3 [16219716.001]
  • [Cites] Arch Surg. 2006 May;141(5):489-94; discussion 494-6 [16702521.001]
  • (PMID = 20215358.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227957
  •  go-up   go-down


34. Krysiak R, Okopień B, Herman ZS: [Insulinoma]. Pol Merkur Lekarski; 2007 Jan;22(127):70-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulinoma is considered the most common endocrine tumour of the pancreas with an annual prevalence of 4 cases per million people.
  • Contrary to the other endocrine tumours of this organ, over 90% of the insulinomas are benign in nature.
  • The clinical presentation of this neoplasm depends on excessive production of insulin and pro-insulin and is characterised by the symptoms of neuroglycopenia and catecholamine response.
  • Effective management requires directed biochemical testing, careful choice of preoperative imaging tests, and complete pancreatic exploration by an experienced endocrine surgeon utilising intraoperative ultrasound.
  • The only curative treatment for insulinoma is complete resection of the tumour.
  • The aim of this paper is to critically discuss contemporary diagnosis and treatment of this neoplasm on the basis of progress made in recent years.
  • [MeSH-major] Adenoma, Islet Cell / complications. Adenoma, Islet Cell / diagnosis. Insulinoma / complications. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endocrine Surgical Procedures / methods. Gastrinoma / complications. Gastrinoma / diagnosis. Gastrinoma / metabolism. Gastrinoma / surgery. Humans. Hypoglycemia / complications. Insulin / metabolism. Pancreatectomy / methods. Prognosis. Rare Diseases

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17477096.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Insulin
  • [Number-of-references] 34
  •  go-up   go-down


35. Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M: Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol; 2010 Jun;23(6):824-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.
  • Pancreatic endocrine tumors are rare diseases and devising a clinically effective prognostic stratification of patients is a major clinical challenge.
  • This study aimed at assessing whether the tumor-node-metastasis (TNM)-based staging and proliferative activity-based grading recently proposed by the European NeuroEndocrine Tumors Society (ENETS) have clinical value.
  • TNM was applied to 274 patients with histologically diagnosed pancreatic endocrine tumors operated from 1991 to 2005, with last follow-up at December 2007.
  • According to World Health Organization (WHO) classification, 246 were well-differentiated neoplasms (51 benign, 56 uncertain behavior, 139 carcinomas) and 28 poorly differentiated carcinomas.
  • Survival analysis not only ascertained the prognostic value of the TNM system but also highlighted that in the absence of nodal and distant metastasis, infiltration and tumor dimensions over 4 cm had prognostic significance.
  • In conclusion, WHO classification assigns clinically significant diagnostic categories to pancreatic endocrine tumors that need prognostic stratification by applying a staging system.
  • The modified TNM described in this study ameliorates the clinical applicability and prediction of outcome of the ENETS-TNM; it (i) assigns a risk of death proportional to the stage at the time of diagnosis, and (ii) allows a clinically based staging of patients, as the T parameters as modified permit their clinical-radiological recognition.
  • [MeSH-major] Carcinoma / diagnosis. Cell Proliferation. Ki-67 Antigen / analysis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Italy. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Prospective Studies. Risk Assessment. Risk Factors. Time Factors. World Health Organization


36. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, Nicol DL, Clements JA: Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer; 2005 Sep;12(3):631-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
  • Prostate-specific antigen (PSA) and the related kallikrein family of serine proteases are current or emerging biomarkers for prostate cancer detection and progression.
  • In this study, we now show that the comparative expression of hK4 protein in prostate cancer tissues, compared with benign glands, is greater than that of PSA and kallikrein 2 (KLK2/hK2), suggesting that hK4 may play an important functional role in prostate cancer progression in addition to its biomarker potential.
  • We hypothesised that this increase in motility displayed by the hK4 and PSA-expressing PC-3 cells may be related to the observed change in structure in these cells from a typical rounded epithelial-like cell to a spindle-shaped, more mesenchymal-like cell, with compromised adhesion to the culture surface.
  • Thus, the expression of E-cadherin and vimentin, both associated with an epithelial-mesenchymal transition (EMT), was investigated.
  • E-cadherin protein was lost and mRNA levels were significantly decreased in PC-3 cells expressing hK4 and PSA (10-fold and 7-fold respectively), suggesting transcriptional repression of E-cadherin, while the expression of vimentin was increased in these cells.
  • The loss of E-cadherin and associated increase in vimentin are indicative of EMT and provides compelling evidence that hK4, in particular, and PSA have a functional role in the progression of prostate cancer through their promotion of tumour cell migration.
  • [MeSH-major] Cadherins / metabolism. Kallikreins / metabolism. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / pathology
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Cell Movement. Epithelial Cells / pathology. Humans. Male. Mesoderm / pathology. Neoplasm Invasiveness


37. Mitra S, Jha M, Gandhi K: Does thyroxine suppression therapy help to rationalize surgery in benign euthyroid nodules? Indian J Nucl Med; 2010 Apr;25(2):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does thyroxine suppression therapy help to rationalize surgery in benign euthyroid nodules?
  • BACKGROUND: Nodular thyroid disease is a common endocrine problem.
  • Most thyroid nodules are benign hyperplastic lesions, but 5-20% may be a true neoplasm.
  • It is important to differentiate a benign from a malignant nodule early as the approach to treatment in the two is radically different.
  • Early institution of medical management in a benign nodule may obviate the need for surgery.
  • PURPOSE OF THE STUDY: The present work aims to study the efficacy of thyroxine suppression in the management of benign thyroid nodules.
  • Based on the investigations, patients were segregated in Group A (toxic nodular goiter), Group B (benign euthyroid nodule) and Group C (malignant nodule).
  • CONCLUSION: The response rate of benign euthyroid nodule to thyroxine suppression was 76% in the present study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188065.001).
  • [ISSN] 0974-0244
  • [Journal-full-title] Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
  • [ISO-abbreviation] Indian J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3003285
  • [Keywords] NOTNLM ; Benign / diagnosis / thyroid nodule / thyroxine suppression
  •  go-up   go-down


38. Kumagai A, Namba H, Akanov Z, Saenko VA, Meirmanov S, Ohtsuru A, Yano H, Maeda S, Anami M, Hayashi T, Ito M, Sagandikova S, Eleubaeva Z, Mussinov D, Espenbetova M, Yamashita S: Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J; 2007 Jun;54(3):399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have applied the PCR-RFLP method using fine-needle aspiration biopsy samples not only to our clinical practice but also to the international medical assistance effort around the Semipalatinsk Nuclear Testing Site in Kazakhstan.
  • Of these cases, we found mutations in one cytologically "suspicious" case and even in two pathologically "benign" cases (after surgery in Kazakhstan).
  • In summary, our PCR-RFLP method for BRAF(T1799A) detection using FNAB samples is useful not only for preoperative diagnosis of PTC but also as a complementary diagnostic tool for accurate pathological diagnosis, even after surgery.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. DNA Mutational Analysis. Diagnostic Techniques, Endocrine. Preoperative Care. Proto-Oncogene Proteins B-raf / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. DNA, Neoplasm / analysis. Female. Humans. Japan. Kazakhstan. Male. Middle Aged. Polymorphism, Restriction Fragment Length


39. Horiguchi A, Miyakawa S, Ishihara S, Ito M, Asano Y, Furusawa K, Shimizu T, Yamamoto T: Surgical design and outcome of duodenum-preserving pancreatic head resection for benign or low-grade malignant tumors. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):792-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical design and outcome of duodenum-preserving pancreatic head resection for benign or low-grade malignant tumors.
  • To apply duodenum-preserving pancreatic head resection (DPPHR) as radical procedure for benign or low-grade malignant tumors, it needs the reconciliation of complete pancreatic head resection and preservation of the bile duct and peripancreatic vessels.
  • We performed 21 DPPHRs and 19 PPPDs in the patients with benign or low-grade malignant pancreatic head tumor.
  • Both exocrine and endocrine function and the long-term results following DPPHR were superior to those following PPPD.
  • The DPPHR should be favored over the PPPD in benign or low-grade malignant tumors of the head of the pancreas if there is no compromise with oncologic radicality.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods
  • [MeSH-minor] Angiography. Female. Follow-Up Studies. Humans. Laparotomy. Length of Stay. Male. Middle Aged. Neoplasm Staging. Pancreas / blood supply. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894017.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML: Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med; 2005 Jan;257(1):38-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience.
  • Multiple endocrine neoplasia type 1 (MEN1) gastro-entero-pancreatic (GEP) tumours develop from the pancreatic islets and from the endocrine cells of the duodenal and gastric mucosa.
  • Even if GEP tumours have generally a benign course, a subgroup of them shows an aggressive behaviour and is a major cause of death amongst MEN1 patients.
  • Diagnosis of insulinoma should lead promptly to pancreatic surgery.
  • Cure rate for Zollinger-Ellison syndrome in MEN1 is low when surgery is limited to tumour enucleation or full thickness duodenal wall resection.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery
  • [MeSH-minor] Gastrinoma / surgery. Humans. Insulinoma / surgery. Neoplasm Metastasis / therapy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Prognosis. Stomach Neoplasms / surgery. Time Factors


41. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Müller-Hermelink HK, Allolio B, Fassnacht M: Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer; 2009 Sep;16(3):919-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value.
  • Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands.
  • GLUT1 and -3 were expressed in 33 and 17% of ACC samples respectively, but in none of the benign tumours or normal adrenals glands.
  • By contrast, TKTL1 and M2-PK were detectable in all benign tissues and the vast majority of ACCs.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / metabolism. Glucose Transporter Type 1 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Female. Glucose / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465749.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; IY9XDZ35W2 / Glucose
  •  go-up   go-down


42. Aiba M, Fujibayashi M: Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol; 2005;16(1):13-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.
  • A great majority of adrenocortical tumors are benign, and many adrenocortical carcinomas (ACC) are obviously malignant at presentation.
  • The histopathological diagnosis of ACC is occasionally difficult, particularly with stage I and stage II disease.
  • The third was a pediatric patient with a tumor showing a nodule-in-nodule pattern with insulin-like growth factor II expression.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic. Adult. Aged. Aged, 80 and over. Aldosterone / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / pathology. Female. Humans. Immunohistochemistry. Infant. Insulin-Like Growth Factor II / metabolism. Male. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] J Biol Chem. 1991 Jun 15;266(17):10731-4 [2040591.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):867-81 [12826878.001]
  • [Cites] Endocr Pathol. 2002 Summer;13(2):141-8 [12165663.001]
  • [Cites] Cancer. 2002 May 1;94(9):2333-43 [12015757.001]
  • [Cites] Surgery. 1992 Dec;112(6):981-6 [1360713.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):175-8 [9024511.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Endocr Pathol. 2003 Summer;14(2):107-16 [12858000.001]
  • [Cites] Pathol Int. 2004 Apr;54(4):273-8 [15028030.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Acta Pathol Jpn. 1979 Mar;29(2):177-82 [552791.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Am J Clin Pathol. 1991 Sep;96(3):334-40 [1652202.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):2048-56 [10843195.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):742-51 [12920217.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:1-53 [1736241.001]
  • [Cites] Am J Pathol. 1981 Jun;103(3):404-10 [7195152.001]
  • [Cites] Am J Pathol. 1986 Dec;125(3):431-5 [2432790.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1385-92 [11745214.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 16000842.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 4964P6T9RB / Aldosterone; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


43. Melotti G, Cavallini A, Butturini G, Piccoli M, Delvecchio A, Salvi C, Pederzoli P: Laparoscopic distal pancreatectomy in children: case report and review of the literature. Ann Surg Oncol; 2007 Mar;14(3):1065-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Laparoscopic resection of benign tumors of the pancreas has been reported in adults, but only four cases of partial laparoscopic pancreatectomy in children have been described in the English-language literature.
  • METHODS: We describe the case of an 11-year-old girl with a solid pseudopapillary tumor who was treated with a laparoscopic, spleen-preserving, distal pancreatectomy.
  • Twenty-two months after the operation, clinical follow-up (including assessment of exocrine and endocrine pancreatic function) revealed nothing abnormal.
  • [MeSH-major] Cystadenoma, Papillary / surgery. Laparoscopy / methods. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Biopsy. Child. Female. Humans. Neoplasm Seeding

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206487.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Mofid AR, Yazdani T, Shahrzad M, Seyedalinaghi S, Zandieh S: Role of fine-needle aspiration in the management of thyroid nodules. Saudi Med J; 2009 Apr;30(4):515-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: As a retrospective study, reports of 888 FNABs of the thyroid performed during a period of 11 years (1996-2007) at Tehran University of Medical Sciences, Sina Hospital and Endocrine Clinic, Tehran, Iran were reviewed.
  • RESULTS: The cytology diagnoses by FNAB were: papillary 6 (3.2%); follicular neoplasm 51 (28%); follicular adenoma 10 (5.4%); Hurthle cell neoplasm 8 (4.3%); suspicious 20 (10.9%); inconclusive 2 (1%); and benign 85 (46.4%).
  • Due to surgery pathologic reports, malignant cytologies were: 6 (100%) for papillary, 1 (1.96%) for follicular neoplasm, 4 (50%) for Hurthle cell neoplasm.
  • [MeSH-major] Goiter, Nodular / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370278.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


45. Jonkers YM, Claessen SM, Perren A, Schmid S, Komminoth P, Verhofstad AA, Hofland LJ, de Krijger RR, Slootweg PJ, Ramaekers FC, Speel EJ: Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Relat Cancer; 2005 Jun;12(2):435-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endocrine pancreatic tumors (EPTs) comprise a highly heterogeneous group of tumors with different clinical behavior and genetic makeup.
  • For the identification of reliable indicators of metastatic disease, we investigated 62 sporadic insulinomas (44 benign and 18 tumors with metastases) by means of comparative genomic hybridization (CGH).
  • In addition, the role of MEN1 (multiple endocrine neoplasia type 1) gene mutations was determined to assess specific chromosomal alterations associated with dysfunction of this endocrine tumor-related tumor suppressor gene.
  • CGH analysis revealed that the total number of aberrations per tumor differs strongly between the benign and the malignant group (4.2 vs 14.1; P<0.0001).
  • Furthermore, chromosome 9q gain was found to be the most frequent aberration in both benign and malignant insulinomas, whereas chromosome 6q losses and 12q, 14q and 17pq gains are strongly associated with metastatic disease.
  • Our study shows that chromosomal instability, as defined by > or =5 gains together with > or =5 losses, or total number of gains and losses > or =8, rather than parameters such as tumor size and proliferation index, is the most powerful indicator for the development of metastatic disease in patients with sporadic insulinoma.
  • [MeSH-major] Chromosomal Instability / genetics. Insulinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Mutation. Neoplasm Metastasis. Nucleic Acid Hybridization. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947114.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


46. Miyamoto H, Molena DA, Schoeniger LO, Haodong Xu: Solitary fibrous tumor of the pancreas: a case report. Int J Surg Pathol; 2007 Jul;15(3):311-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pancreas: a case report.
  • Solitary fibrous tumor (SFT) is an unusual mesenchymal neoplasm that most often arises in the pleura; however, it has recently been described in a number of extrapleural sites.
  • This report describes an extremely rare case of a benign SFT arising in the pancreas.
  • An endocrine tumor was clinically suspected.
  • Microscopically, the tumor was composed of bland uniform spindle cells arranged between collagen bundles.
  • Based on the light microscopic morphology and immunohistochemical staining profile, the diagnosis of SFT was rendered.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652547.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


47. Queiroga FL, Pérez-Alenza D, Silvan G, Peña L, Lopes CS, Illera JC: Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci; 2010 Dec;89(3):396-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormonal determinations were done by enzyme immunoassays techniques validated for canine species in serum and tumour tissue from 32 bitches with CMT and in serum and normal mammary tissue from 10 controls.
  • Serum and tissular GH and IGF-I concentrations were significantly higher in the case of malignant tumour compared with benign and controls.
  • GH and IGF-I elevated concentrations were significantly associated with tumour relapse and/or metastases during follow-up and in dogs with reduced survival times; however these parameters were not independent prognostic factors in multivariate analysis.
  • This association demonstrates a link between high serum and intratumoural GH and IGF-I concentrations and a worse prognosis and opens the possibility to new anticancer endocrine therapies in dogs.
  • [MeSH-major] Breast Neoplasms / veterinary. Dog Diseases / diagnosis. Growth Hormone / blood. Insulin-Like Growth Factor I / analysis
  • [MeSH-minor] Animals. Breast / chemistry. Breast / pathology. Dogs. Estrogen Receptor alpha / analysis. Female. Immunoenzyme Techniques / veterinary. Neoplasm Metastasis. Prognosis. Prospective Studies. Receptors, Progesterone / analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20381105.001).
  • [ISSN] 1532-2661
  • [Journal-full-title] Research in veterinary science
  • [ISO-abbreviation] Res. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


48. Türköz HK, Oksüz H, Yurdakul Z, Ozcan D: Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol; 2008;19(2):92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma.
  • Galectin-3 expression has been evaluated in various malignant neoplasms to determine its effectiveness in differential diagnosis from benign lesions and its effects on carcinogenesis.
  • We studied the presence of galectin-3 expression immunohistochemically and its relation with tumor invasiveness and lymph node metastasis in 89 cases of papillary carcinoma of the thyroid.
  • Galectin-3 overexpression is more profound in early stages of papillary carcinoma, and its expression intensity decreases during tumor progression.
  • This finding is consistent with roles for galectin-3 in cell adhesion to other tumor cells and the matrix.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Galectin 3 / biosynthesis. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aging / pathology. Biomarkers, Tumor. Disease Progression. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Metastasis / pathology. Paraffin Embedding. Retrospective Studies. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1998 Jun;12(6):1287-90 [9592187.001]
  • [Cites] J Pathol. 1996 May;179(1):43-8 [8691344.001]
  • [Cites] Cell Mol Biol Lett. 2004;9(2):305-28 [15213811.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Head Neck. 2005 Dec;27(12):1049-55 [16155918.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):428-33 [10821488.001]
  • [Cites] Int J Oncol. 1999 Jul;15(1):143-8 [10375607.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):787-92 [11251175.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1069-75 [11891203.001]
  • [Cites] Am J Clin Pathol. 2006 Mar;125(3):399-406 [16613343.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Aug;25(4):319-30 [10476049.001]
  • [Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Exp Cell Res. 1998 Dec 15;245(2):294-302 [9851870.001]
  • [Cites] Acta Cytol. 2006 Sep-Oct;50(5):518-28 [17017437.001]
  • [Cites] J Natl Cancer Inst. 1992 Aug 5;84(15):1161-9 [1386115.001]
  • [Cites] Biochem Soc Trans. 1992 May;20(2):269-74 [1397610.001]
  • [Cites] Int J Cancer. 2000 Feb 15;85(4):545-54 [10699929.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6):1906-15 [9394730.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • (PMID = 18581271.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


49. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • The patient underwent genetic testing for Cowden syndrome (PTEN gene), Carney complex (PRKAR1A gene), and multiple endocrine neoplasia syndrome type 1 (MEN1 gene); no deleterious mutations were identified.
  • DISCUSSION: The constellation of benign and malignant neoplasms in the context of this patient's familial testicular cancer raised the possibility that these might be manifestations of a known hereditary susceptibility cancer syndrome; however, genetic testing for the three syndromes that were most likely to explain these findings did not show any mutation.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.
  • This possibility cannot be evaluated definitively on the basis of a single case report; additional observations and studies are necessary to investigate this hypothesis further.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


50. Imaoka H, Yamao K, Bhatia V, Shimizu Y, Yatabe Y, Koshikawa T, Kinoshita Y: Rare pancreatic neoplasms: the utility of endoscopic ultrasound-guided fine-needle aspiration-a large single center study. J Gastroenterol; 2009;44(2):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare pancreatic neoplasms: the utility of endoscopic ultrasound-guided fine-needle aspiration-a large single center study.
  • We describe the performance and pitfalls of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for diagnosis of these rare pancreatic tumors and their characteristic cytopathological features.
  • The reference standard for final diagnosis was surgical pathology from resected specimens.
  • Overall, EUS-FNA with the results of cytology, cell-block processing, and immunohistochemistry could correctly diagnose the type of neoplasm in 19 (67.9%) cases.
  • EUS-FNA could distinguish benign from malignant rare tumors with a sensitivity of 69.2%, a specificity of 100%, positive predictive value of 100%, negative predictive value of 79.0%, and accuracy of 85.7%.
  • None of three malignant pancreatic endocrine neoplasms could be diagnosed as malignant.
  • An adequate core tissue sample could be obtained in 21 cases (75.0%) and provide a histopathological diagnosis in 19 (67.9%) cases.
  • EUS-FNA could change the presumptive diagnosis in 11 (39.3%) cases.
  • Specific immunochemical studies were useful adjuncts to the diagnosis.
  • CONCLUSIONS: Pancreatic neoplasms other than ductal adenocarcinomas have diverse imaging and histopathological features.
  • [MeSH-major] Endosonography. Pancreatic Neoplasms / diagnostic imaging. Pancreatic Neoplasms / pathology. Surgery, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):701-6 [14595305.001]
  • [Cites] Gastrointest Endosc. 1997 May;45(5):387-93 [9165320.001]
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):346-51 [11985973.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):291-6 [12145615.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):219-22 [12584640.001]
  • [Cites] Dig Dis Sci. 2002 Aug;47(8):1839-42 [12184539.001]
  • [Cites] Acta Cytol. 1992 Nov-Dec;36(6):881-6 [1449026.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1386-91 [12094855.001]
  • [Cites] JOP. 2004 Jul;5(4):282-8 [15254363.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):233-46 [8575283.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):433-6 [8457156.001]
  • [Cites] Gastrointest Endosc. 1998 Feb;47(2):121-7 [9512275.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):172-3 [1568614.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10 ):974-9 [16234042.001]
  • [Cites] J Surg Oncol. 2003 Jul;83(3):161-6; discussion 166 [12827684.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):76-9 [15672060.001]
  • [Cites] Acta Cytol. 1991 Sep-Oct;35(5):546-8 [1927196.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):313-8 [15468134.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):267-79 [15278063.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):654-62 [15151205.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):689-96 [15855973.001]
  • [Cites] Am J Surg. 2001 Aug;182(2):183-4 [11574093.001]
  • [Cites] Gut. 2000 Feb;46(2):244-9 [10644320.001]
  • [Cites] Gastrointest Endosc. 2001 Jan;53(1):65-70 [11154491.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):784-8 [14595324.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):815-37 [1384374.001]
  • [Cites] Cancer. 2002 Jun 25;96(3):174-80 [12115306.001]
  • [Cites] Pancreas. 2006 Mar;32(2):223-4 [16552347.001]
  • [Cites] Am J Gastroenterol. 2002 Nov;97(11):2768-75 [12425546.001]
  • (PMID = 19214677.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK, Singh U: Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg; 2010 Dec;34(12):3022-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?
  • The goal of this study was to find a correlation between the tumor size and malignant potential of PCC and determine whether the "Pheochromocytoma of the adrenal gland scaled score" (PASS) proposed by Thompson can be applied to predict malignancy.
  • Tumor size was available for 90 tumors.
  • RESULTS: Of the benign cases, none developed recurrence or metastasis.
  • Of the sporadic benign cases, 21 (41%) patients with tumor size > 6 cm had a PASS of >4, and none of them developed metastasis.
  • No correlation was found between tumor size and PASS > 4 and PASS ≤ 4 (7.8 cm vs. 7.1 cm; p = 0.23).
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Glands / pathology. Neoplasm Staging. Pheochromocytoma / pathology

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1990 May-Jun;14(3):325-9 [1973322.001]
  • [Cites] J Endourol. 2004 Apr;18(3):251-5 [15225390.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Surgery. 2003 Dec;134(6):918-22; discussion 922-3 [14668723.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Anaesth Intensive Care. 2004 Apr;32(2):224-9 [15957720.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):467-72 [7725730.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):651-63 [1479148.001]
  • [Cites] J Surg Oncol. 1992 Aug;50(4):258-62 [1640712.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6 [10363888.001]
  • [Cites] World J Surg. 1996 Sep;20(7):916-21; discussion 922 [8678971.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):599-608 [19145205.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1168-80 [2172151.001]
  • [Cites] World J Surg. 2005 Sep;29(9):1185-8 [16091986.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] Surgery. 2008 Jun;143(6):759-68 [18549892.001]
  • [Cites] Ann Surg. 1974 May;179(5):740-8 [4823849.001]
  • (PMID = 20703467.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Al Harthi B, Riaz MM, Al Khalaf AH, Al Zoum M, Al Shakweer W: Adrenal myelolipoma a rare benign tumour managed laparoscopically: Report of two cases. J Minim Access Surg; 2009 Oct;5(4):118-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal myelolipoma a rare benign tumour managed laparoscopically: Report of two cases.
  • Adrenal Myelolipoma is a rare benign neoplasm composed of mature adipose tissue and a variable amount of haemopoietic elements.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1998 Jul;208(1):87-95 [9646797.001]
  • [Cites] J Urol. 1997 Apr;157(4):1213-6 [9120904.001]
  • [Cites] Surgery. 1973 May;73(5):665-70 [4697085.001]
  • [Cites] J Urol. 1992 Apr;147(4):1089-90 [1552592.001]
  • [Cites] Ir Med J. 2001 Sep;94(8):231-3 [11758622.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Apr;13(2):106-10 [12709616.001]
  • [Cites] J Urol. 1992 Jun;147(6):1478-81 [1593668.001]
  • (PMID = 20407573.001).
  • [ISSN] 1998-3921
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2843128
  • [Keywords] NOTNLM ; Angiomyelolipoma / laparoscopic adrenalectomy / myelolipoma
  •  go-up   go-down


53. Ghosh S, Joy R, Hickey S: Rare presentation of laryngeal neuroma in a patient with multiple endocrine neoplasia type two B. J Laryngol Otol; 2008 Sep;122(9):1012-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare presentation of laryngeal neuroma in a patient with multiple endocrine neoplasia type two B.
  • OBJECTIVE: We present a rare case of laryngeal mucosal neuroma, and its management, in a patient with multiple endocrine neoplasia type 2 B.
  • METHOD: We present a case report and a review of the world literature concerning laryngeal mucosal neuroma and its association with multiple endocrine neoplasia type 2 B.
  • CASE REPORT: An 11-year-old girl was diagnosed with multiple endocrine neoplasia type 2 B on the basis of clinical presentation and genetic testing.
  • Biopsies taken at the time were reported as showing benign mucosal neuromas.
  • CONCLUSION: Multiple endocrine neoplasia syndromes are inherited autosomal cancer syndromes.
  • Laryngeal mucosal neuroma can manifest as potentially airway compromising lesions in patients with multiple endocrine neoplasia type 2 B.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Multiple Endocrine Neoplasia Type 2b / complications. Neuroma / pathology
  • [MeSH-minor] Child. Female. Humans. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666129.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


54. Clemente G, Sarno G, Giordano M, De Rose AM, Giovannini I, Vecchio FM, Nuzzo G: Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication? Minerva Chir; 2007 Oct;62(5):421-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric carcinoid is a relatively rare neoplasm with peculiar features which differentiate it from the intestinal and pulmonary carcinoid and, obviously, from gastric adenocarcinoma.
  • Gastric carcinoids are divided into three different types: Type 1, associated with gastric atrophy and megaloblastic anemia; Type 2, associated with Zollinger-Ellison syndrome within a type 1 multiple endocrine neoplasia (MEN); and Type 3, sporadic tumor not associated with other lesions, particularly invasive and with poor prognosis.
  • It is generally small, multifocal and located in the gastric fundus, has no tendency for vascular invasion and is associated with a benign course.
  • We report a case of a woman with a type 1 gastric carcinoid in which, for the presence of an extended micro-polyposis of the fundus a total gastrectomy was necessary for treatment.
  • [MeSH-major] Carcinoid Tumor / surgery. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947953.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


55. Niederle MB, Hackl M, Kaserer K, Niederle B: Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer; 2010 Dec;17(4):909-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
  • Using the current WHO classification, the tumor, nodes, metastases (TNM) staging and Ki67 grading and the standard diagnostic procedure proposed by the European Neuroendocrine Tumor Society (ENETS), GEP-NETs from 285 patients (male: 148; female: 137) were recorded.
  • The stomach (23%) was the main site, followed by appendix (21%), small intestine (15%) and rectum (14%).
  • Patients with appendiceal tumours were significantly younger than patients with tumours in any other site.
  • About 46.0% were classified as benign, 15.4% as uncertain, 31.9% as well differentiated malignant and 6.7% as poorly differentiated malignant.
  • Patients with benign or uncertain tumours were significantly younger than patients with malignant tumours.
  • NETs of the digestive tract are more common than previously reported; the majority show benign behaviour, are located in the stomach and are well differentiated.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Neuroendocrine Tumors / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Austria / epidemiology. Female. Histocytochemistry. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702725.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Boninsegna L, Partelli S, D'Innocenzio MM, Capelli P, Scarpa A, Bassi C, Pederzoli P, Falconi M: Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology; 2010;92(4):246-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior.
  • BACKGROUND: Cystic pancreatic endocrine tumors (CPETs) are rare lesions and their biological features have been scarcely investigated.
  • AIM: To compare clinical and pathological features of resected non-functioning sporadic CPETs (NF-CPETs) with solid pancreatic endocrine tumors (SPETs) in a single-institution experience.
  • METHODS: All patients with a pathologically confirmed diagnosis of sporadic non-functioning pancreatic endocrine tumors who underwent curative resection between 1990 and 2008 were included.
  • Univariate and multivariable analyses were performed to identify preoperative predictors of carcinoma (non-functioning pancreatic endocrine carcinoma).
  • RESULTS: Twenty-one (11.5%) patients with a histological diagnosis of NF-CPET were identified.
  • The median age was 60 years (IQR 46.5-73.5 years) and a diagnosis of carcinoma (non-functioning pancreatic endocrine carcinoma) was made in 3 (14.3%) cases.
  • The incidence of non-functioning pancreatic endocrine carcinoma was significantly lower in the NF-CPET versus the NF-SPET group (14.3 vs. 40.4%, p = 0.04).
  • By univariate analysis, preoperative predictors of non-functioning pancreatic endocrine carcinoma included the presence of symptoms (OR 3.96, 95% CI 2.06-7.63) and an increase in the absolute value of radiological diameter (OR 1.05, 95% CI 1.03-1.07).
  • CONCLUSIONS: NF-CPETs have a measurable propensity to be benign.
  • In those patients affected by small and asymptomatic NF-CPET a more conservative surgical approach or a follow-up policy could be considered.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Pancreatectomy / methods. Pancreatic Cyst / diagnosis. Pancreatic Cyst / pathology. Survival Analysis


57. Miyakoshi A, Dalley RW, Anzai Y: Magnetic resonance imaging of thyroid cancer. Top Magn Reson Imaging; 2007 Aug;18(4):293-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid cancer is a unique malignancy arising from the endocrine system, and its nature is different from more common squamous cell carcinoma in the head and neck region.
  • Imaging findings of benign and malignant thyroid lesions overlap substantially, and differentiation may be difficult.
  • [MeSH-major] Magnetic Resonance Imaging. Neoplasm Staging. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893594.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


58. He X, Wei Q, Zhang X, Xiao J, Jin X, Zhu Y, Cui B, Ning G: Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract; 2010 Oct 15;206(10):712-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In different tumor entities, expression of the chemokine receptor 4 (CXCR4) has been linked to tumor dissemination and poor prognosis.
  • The aim of this study was to examine the immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In our study, the CXCR4 expression of the thyroid carcinoma group (including 16 papillary thyroid carcinomas, 18 follicular thyroid carcinomas, 9 poorly differentiated thyroid carcinomas, and 7 medullary thyroid carcinomas) was found to be higher than in the benign lesion group (including 19 cases of Hashimoto's thyroiditis, 15 nodular goiters, and 50 follicular adenomas) (p<0.0001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Receptors, CXCR4 / analysis. Thyroid Diseases / immunology
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Carcinoma. Carcinoma, Neuroendocrine. Cell Differentiation. Child. Female. Goiter, Nodular / immunology. Hashimoto Disease / immunology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Thyroid Neoplasms / immunology. Thyroid Neoplasms / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20646838.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCR4 protein, human; 0 / Receptors, CXCR4; Thyroid cancer, medullary; Thyroid cancer, papillary
  •  go-up   go-down


59. Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P: Enucleation of pancreatic neoplasms. Br J Surg; 2007 Oct;94(10):1254-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enucleation of pancreatic neoplasms.
  • BACKGROUND: Standard resections for benign and borderline neoplasms of the pancreas are associated with a significant risk of long-term functional impairment, whereas enucleation preserves healthy parenchyma and pancreatic function.
  • A clinically significant pancreatic fistula was reported in 14 patients (23 per cent), and five patients (8 per cent) had a further operation for fistula-related complications.
  • The most common indication for surgery was endocrine neoplasm (38 patients; 62 per cent) and two patients (3 per cent) had a final histopathological diagnosis of malignant neoplasm.
  • At a median follow-up of 61 months no patient had developed tumour recurrence or exocrine insufficiency.
  • Two elderly patients developed non-insulin-dependent diabetes.
  • CONCLUSION: Enucleation is an effective procedure for the radical treatment of benign and borderline neoplasms of the pancreas, with good long-term outcomes.
  • [MeSH-major] Pancreatic Fistula / etiology. Pancreatic Neoplasms / surgery. Postoperative Complications / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 British Journal of Surgery Society Ltd.
  • [CommentIn] Br J Surg. 2008 Feb;95(2):261; author reply 261-2 [18196559.001]
  • (PMID = 17583892.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


60. Vanbeckevoort D: Solid pancreatic masses: benign or malignant. JBR-BTR; 2007 Nov-Dec;90(6):487-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pancreatic masses: benign or malignant.
  • Solid masses in the pancreas mostly occur in the pancreatic head and may be related to inflammation due to chronic pancreatitis or may be caused by malignancy.
  • Ductal pancreatic carcinoma is the most common malignant pancreatic neoplasm, accounting for more than 90% of malignant solid pancreatic tumours.
  • Endocrine tumours represent only a minority of those tumours.
  • While endocrine tumours tend to exhibit symptoms earlier in the course of the disease (due to tumour-related hormone production), adenocarcinomas present in nearly all cases in advanced stages when curative resection is not feasible.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endocrine Gland Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376761.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 13
  •  go-up   go-down


61. Delemer B: [Prolactinomas: diagnosis and treatment]. Presse Med; 2009 Jan;38(1):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prolactinomas: diagnosis and treatment].
  • [Transliterated title] Adénomes à prolactine : diagnostic et prise en charge.
  • Their diagnosis follows clear and increasingly simple rules.
  • Microadenomas are benign and nonaggressive; inducing gonadotropin insufficiency, they present endocrine problems and have harmful consequences on fertility and on overall health status.
  • [MeSH-major] Pituitary Neoplasms / diagnosis. Prolactinoma / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Antineoplastic Agents, Hormonal / therapeutic use. Contraceptives, Oral, Hormonal / therapeutic use. Diagnosis, Differential. Dopamine Agonists / therapeutic use. Female. Gonadotropins / secretion. Hormone Replacement Therapy. Humans. Hyperprolactinemia / diagnosis. Hypothyroidism / diagnosis. Neoadjuvant Therapy. Neoplasm Invasiveness. Neurosurgical Procedures. Patient Care Planning. Pregnancy. Pregnancy Complications, Neoplastic / physiopathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056203.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptives, Oral, Hormonal; 0 / Dopamine Agonists; 0 / Gonadotropins
  •  go-up   go-down


62. Fendrich V, Waldmann J, Bartsch DK, Langer P: Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol; 2009 Jul;6(7):419-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of pancreatic endocrine tumors.
  • Pancreatic endocrine tumors (PETs) are uncommon but clinically challenging and fascinating tumors with an annual incidence of 1 per 100,000 people.
  • Functional tumors are commonly associated with a specific hormonal syndrome directly related to a hormone secreted by the tumor, such as Zollinger-Ellison syndrome or organic hyperinsulinism.
  • Small, benign neoplasms, such as 90% of all insulinomas, are readily curable by surgical resection; however, most other functional and all nonfunctional pancreatic tumors have a much less favorable prognosis.
  • Many features of the management of pancreatic endocrine tumors, such as timing and extent of resection, and the use of laparoscopic procedures, are currently under debate.
  • This Review describes the current status of surgical treatment for pancreatic endocrine tumors, and discusses the new developments in this field.
  • [MeSH-major] Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Endoscopy, Digestive System / methods. Humans. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506584.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 77
  •  go-up   go-down


63. Ouaïssi M, Sielezneff I, Alves A, Pirro N, Heyries L, Robitail S, Consentino B, Payan MJ, Valleur P, Panis Y, Sastre B: [Long term outcome following 26 surgical ampullectomies]. Ann Chir; 2006 May;131(5):322-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Résultat à long terme de 26 ampullectomies chirurgicales.
  • Ampullectomy is an alternative to PD for benign ampulloma or, in high-risk patients, for invasive carcinoma.
  • The aim of this study was to report early and long term results of surgical ampullectomy for presumed benign ampullomas.
  • RESULTS: Final pathological examination revealed 15 adenomas, 4 in situ adenocarcinomas, 2 endocrine tumors, and 5 other benign lesions.
  • CONCLUSION: Ampullectomy is a good alternative to PD in case of benign or non-invasive malignant ampullary lesion, including in selected cases of FAP.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adenomatous Polyposis Coli / surgery. Adult. Aged. Carcinoma in Situ / surgery. Cause of Death. Common Bile Duct Diseases / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / surgery. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies. Somatostatinoma / surgery. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615931.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


64. Han XN, Chen B, Ye XD, Wang J, Liu GH: [Clinical manifestation and multiphasic spiral CT scanning features of abdominal pheochromocytoma: report of 70 cases]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among the 70 patients, there were 41 patients with endocrine symptoms related to pheochromocytoma, 15 had a latent pheochromocytoma and the remaining 14 cases presented with a non-functioning pheochromocytoma.
  • Sixty cases had a tumor located in the adrenal gland, while 8 in retroperitoneal space, and 2 cases had both intraadrenal and ectopic lesions simultaneously.
  • Sixty patients had a benign pheochromocytoma, the other 10 had a malignant one or relapse after operation.
  • The average size of the tumor was 5.8 cm (range, 2 approximately 15 cm in the longest diameter).
  • CONCLUSION: Approximately half of the abdominal pheochromocytomas are lack of endocrine symptoms related with their tumors.
  • However, they may display some typical CT characteristics, such as that a small lesion is often homogeneous but hypervascular, a larger tumor may present hemorrhage, necrosis, and cystic change with rich or moderate blood supply.
  • However, when a small tumor has moderate blood supply, it should be differentiated with an adrenal adenoma; when a big one has moderate blood supply, it should be differentiated with other malignant tumors.
  • Furthermore, a part of malignant pheochromocytomas is really difficult to be differentiated from some benign lesions by spiral CT images alone.
  • [MeSH-major] Adrenal Gland Neoplasms / radiography. Pheochromocytoma / radiography. Retroperitoneal Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adenoma / blood supply. Adenoma / radiography. Adenoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiographic Image Enhancement. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538893.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. Sugimoto M, Yasuda H, Koda K, Suzuki M, Yamazaki M, Tezuka T, Kosugi C, Higuchi R, Takenoue T, Yamamoto S, Watayo Y, Yagawa Y, Tsuchiya T: Virtual CO2 MDCT pancreatography: a new feasible technique for minimally invasive pancreatectomy in intraductal papillary mucinous neoplasms. Hepatogastroenterology; 2008 Jan-Feb;55(81):270-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virtual CO2 MDCT pancreatography: a new feasible technique for minimally invasive pancreatectomy in intraductal papillary mucinous neoplasms.
  • BACKGROUND/AIMS: Less invasive pancreatic head resection, such as duodenum-preserving pancreatic head resection (DPPHR) has been introduced for the treatment of pancreatoduodenal lesions, especially for benign conditions, for reducing surgical stress and maintaining exocrine and endocrine function of the residual pancreas in consideration of postoperative quality of life (QOL).
  • METHODOLOGY: We investigated the feasibility of a new technique employing three-dimensional (3D) virtual pancreatography using multi-detector CT (MDCT) with carbon dioxide (CO2) gas as a negative contrast agent for detection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas requiring minimally invasive surgery.
  • For localizing diagnosis of these small and multiple pancreatic cysts, we placed an endoscopic pancreatic stent (EPS), and MDCT with injection of CO2 via EPS was examined for the virtual CO2 pancreatography, consisting of OsiriX software system employing 3D virtual anatomic reconstruction with CO2 gas as a negative contrast agent.
  • We performed DPPHR, and surgical margin of the patient's remnant pancreas was determined as non-malignant by intraoperative histology.
  • There was no residual pancreatic cyst and tumor after surgery.
  • The resected tumor was diagnosed as branch duct type intraductal papillary mucinous adenocarcinoma.
  • According to our minimally invasive DPPHR obtained by virtual CO2 pancreatography, the pancreatic endocrine and exocrine functions of this patient were maintained at almost the same levels as those in his preoperative status.
  • With respect to preservation of the endocrine and exocrine functions of the pancreas, DPPHR is a highly effective surgical procedure due to limited surgical resection.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Carcinoma, Pancreatic Ductal / radiography. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / radiography. Pancreatic Neoplasms / surgery. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507123.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


66. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • CONCLUSIONS: VHL syndrome is a multisystem disorder with a poor prognosis and a high rate of missed diagnosis.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


67. Imai Y, Taketani T, Maemura K, Takeda N, Harada T, Nojiri T, Kawanami D, Monzen K, Hayashi D, Murakawa Y, Ohno M, Hirata Y, Yamazaki T, Takamoto S, Nagai R: Genetic analysis in a patient with recurrent cardiac myxoma and endocrinopathy. Circ J; 2005 Aug;69(8):994-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 60 year-old male was referred for treatment of a cardiac myxoma in the right atrium.
  • He had a past history of left atrial cardiac myxoma at age 49 and pituitary microadenoma related to acromegaly at age 55.
  • He did not have a family history of cardiac neoplasm or endocrinopathy.
  • The intracardiac tumor was resected and its pathology was compatible with myxoma.
  • A diagnosis of Carney complex (CNC) was made because the diagnostic criteria of this neoplastic syndrome were satisfied by the presence of recurrent cardiac myxoma, endocrine tumor and spotty skin pigmentation.
  • Although it is the most common, usually benign, cardiac tumor, myxoma can cause a critical clinical situation and thus detecting the PRKAR1A mutation can assist with prognosis.
  • [MeSH-major] Endocrine Gland Neoplasms / genetics. Heart Neoplasms / genetics. Mutation. Myxoma / genetics. Proteins / genetics
  • [MeSH-minor] Acromegaly / complications. Acromegaly / diagnosis. Acromegaly / genetics. Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. Cyclic AMP-Dependent Protein Kinases. Humans. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041174.001).
  • [ISSN] 1346-9843
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / PRKAR1A protein, human; 0 / Proteins; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  •  go-up   go-down


68. Kardel E, Gołabek K, Kostro JZ, Sledziński Z: Mucinous cystadenocarcinomas of the pancreas. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):692-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: The purpose of this study was to evaluate the clinicopathologic characteristics, diagnosis and treatment of mucinous cystadenocarcinomas (MCACs) of the pancreas.
  • METHODOLOGY: This is a retrospective review of 6 patients who underwent curative resection for MCACs of the pancreas in the Department of General Endocrine and Transplantation Surgery, Medical University of Gdańsk from 1994-2004.
  • Three endoscopic retrograde cholangiopancreatographys (ERCPs) were unhelpful in differentiating between malignant tumor and benign lesion.
  • CONCLUSIONS: Diagnostic accuracy for cystic pancreatic neoplasm is still limited.
  • [MeSH-major] Cystadenocarcinoma, Mucinous. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613435.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


69. Avcu S, Ozen O, Bulut MD, Bora A: Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci; 2009 Nov;1(6):305-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.
  • CONTEXT: Carcinoid tumors represent a group of well-differentiated tumors originating from the diffuse endocrine system outside the pancreas and thyroid.
  • Various sites of origin of this neoplasm are appendix - 30-45%, small bowel - 25-35% (duodenum 2%, jejunum 7%, ileum 91%, multiple sites 15-35%), rectum 10-15%, caecum - 5%, and stomach - 0.5%.
  • CASE REPORT: Here we report a case of primary jejunal carcinoid tumor in a 66-year-old woman metastasizing to liver with ultrasonography, computed tomography, and diffusion-weighted magnetic resonance imaging (DWI) findings.
  • CONCLUSION: Primary jejunal carcinoid tumor is a rare entity.
  • DWI can help in the differential diagnosis of hepatic hypervascular metastatic mass lesions from benign ones, as well as in the diagnosis of carcinoid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666712.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364631
  • [Keywords] NOTNLM ; Carcinoid / diffusion weighted MRI / jejunum / metastases / small bowel
  •  go-up   go-down


70. Kotzampassakis N, Maweja S, Defechereux T, Meurisse M, Hamoir E: Surgical management of adrenal tumours. Lessons from a 10 years personal experience. Acta Chir Belg; 2005 Apr;105(2):156-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lesions resected were preoperatively considered non-secreting in 47 cases (45%) and hormonally active in 58 cases (55%).
  • In 78 patients (80%), LA was performed and 84 adrenal glands were resected.
  • In 19 patients (20%), OA was considered the best modality of resection and 21 adrenal glands were resected.
  • The average tumour size was 37.2 mm (range 25-90) in LA group and 82.6 mm (30-260) in the OA group.
  • CONCLUSIONS: In our experience, trans-peritoneal LA proved to be a safe and reliable procedure for benign adrenal disease.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Diagnostic Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Belgium. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Laparoscopy / methods. Laparotomy / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906906.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


71. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


72. Uehara H, Tatsumi K, Masuda E, Kato M, Kizu T, Ishida T, Takakura R, Takano Y, Nakaizumi A, Ishikawa O, Takenaka A: Scraping cytology with a guidewire for pancreatic-ductal strictures. Gastrointest Endosc; 2009 Jul;70(1):52-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conventional procedures for acquisition of a specimen for cytology during ERCP have been limited in their ability to discriminate pancreatic-ductal strictures.
  • PATIENTS AND METHODS: Eighty-six patients with pancreatic-ductal strictures composed of 71 malignant and 15 benign diseases were evaluated.
  • Malignant diseases included 70 pancreatic carcinomas and 1 endocrine tumor; benign diseases included the following: 7 chronic pancreatitis, 3 autoimmune pancreatitis, 3 idiopathic pancreatic-ductal strictures, and 2 pancreatic cysts.
  • Sensitivities for pancreatic carcinoma with a tumor of <20 mm, 21 to 40 mm, 41 to 60 mm, and >61 mm were 95%, 92%, 100%, and 100%, respectively.
  • CONCLUSIONS: Benign or malignant pancreatic-ductal strictures were accurately discriminated by scraping cytology with a guidewire during ERCP.
  • The technique yielded high diagnostic sensitivities in pancreatic carcinoma, regardless of the location or size of the tumor.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249043.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Ng VW, Ma RC, So WY, Choi KC, Kong AP, Cockram CS, Chow CC: Evaluation of functional and malignant adrenal incidentalomas. Arch Intern Med; 2010 Dec 13;170(22):2017-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We undertook this study to review the clinical characteristics of patients with adrenal incidentalomas who presented to a tertiary endocrine center in Hong Kong.
  • METHODS: Retrospective review of all 139 cases of adrenal incidentalomas that were referred to the Endocrine Centre of the Prince of Wales Hospital between June 1, 2000, and May 31, 2007.
  • We reviewed detailed patient history, physical examination findings, and symptoms and signs related to hormonal hypersecretion or malignant neoplasm and recorded clinical indications for performing diagnostic radiological imaging.
  • RESULTS: Sixty-one patients (43.9%) had nonfunctional benign adrenal adenomas, 52 (37.4%) had functional lesions, 15 (10.8%) had malignant adrenal lesions, and the remaining 11 (7.9%) had varying adrenal disease.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Aldosterone / secretion. Catecholamines / secretion. Hydrocortisone / secretion

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21149760.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; 4964P6T9RB / Aldosterone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone; Adrenal incidentaloma
  •  go-up   go-down


74. Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET: Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol; 2007;18(2):79-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.
  • Insulinomas constitute a subgroup of pancreatic endocrine tumors showing B cell differentiation and clinical symptoms related to inappropriate insulin secretion (WHO).
  • Many endocrine tumors express somatostatin receptors (sstrs), which can be visualized by octreotide scintigraphy; however, about half of all insulinomas are reported to be negative.
  • In the present study, the immunoreactivity to all five human sstr was studied in ten benign and six malignant human insulinomas.
  • Sstr4 was the receptor subtype most frequently expressed in both benign and malignant tumors.
  • A difference in the immunohistochemical sstr5 expression pattern was seen between benign and malignant tumors: Three of the six malignant tumors, but none of the benign tumors, expressed sstr5.
  • The other receptor subtypes were expressed in low numbers with no difference between benign and malignant tumors.
  • The finding of a strong expression of sstr4 in both benign and malignant insulinomas suggests that this receptor subtype could be of importance for diagnostic and therapeutic use.
  • [MeSH-major] Insulinoma / genetics. Insulinoma / metabolism. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Receptors, Somatostatin / biosynthesis. Receptors, Somatostatin / genetics
  • [MeSH-minor] Animals. Blotting, Western. COS Cells. Cercopithecus aethiops. Electrophoresis, Polyacrylamide Gel. Humans. Immunohistochemistry. Membrane Proteins / biosynthesis. Membrane Proteins / genetics. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Tissue Fixation. Transfection

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):132-6 [16625862.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):69-78 [16601280.001]
  • [Cites] Virchows Arch. 2002 May;440(5):461-75 [12021920.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:535-46 [15338762.001]
  • [Cites] Br J Surg. 2001 Jan;88(1):31-40 [11136306.001]
  • [Cites] Eur J Clin Invest. 1997 Aug;27(8):639-44 [9279525.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2315-9 [7907795.001]
  • [Cites] Surg Today. 2002;32(8):690-4 [12181718.001]
  • [Cites] Cell Physiol Biochem. 2002;12 (1):31-8 [11914546.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):844-52 [8373420.001]
  • [Cites] Can J Biochem. 1974 Nov;52(11):1067-72 [4609582.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2534-41 [9667275.001]
  • [Cites] Med Oncol. 2003;20(1):59-67 [12665686.001]
  • [Cites] Mol Endocrinol. 1992 Dec;6(12):2136-42 [1337145.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3455-9 [8012966.001]
  • [Cites] J Clin Invest. 1994 Mar;93(3):1321-5 [8132773.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5353-60 [14602773.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5969-77 [2168286.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]
  • [Cites] Eur J Endocrinol. 2005 May;152(5):757-67 [15879362.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Jun;8(2):126-32 [10937060.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2375-8 [9622077.001]
  • [Cites] Gut. 2002 Jan;50(1):52-60 [11772967.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):107-12 [15248829.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):251-5 [1346068.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):3011-8 [9284735.001]
  • [Cites] J Nucl Med. 2000 Mar;41(3):459-62 [10716319.001]
  • [Cites] Mol Endocrinol. 1996 Dec;10(12):1688-96 [8961277.001]
  • (PMID = 17916997.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Receptors, Somatostatin; 0 / somatostatin receptor subtype-4
  •  go-up   go-down


75. Owston MA, Ramsay EC, Rotstein DS: Neoplasia in felids at the Knoxville Zoological Gardens, 1979-2003. J Zoo Wildl Med; 2008 Dec;39(4):608-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplasia in felids at the Knoxville Zoological Gardens, 1979-2003.
  • A review of medical records and necropsy reports from 1979-2003 found 40 neoplasms in 26 zoo felids, including five lions (Panthera leo, two males and three females), three leopards (Panthera pardus, two males and one female), one jaguar (Panthera onca, female), 11 tigers (Panthera tigris, three males and eight females), two snow leopards (Panthera uncia, one male and one female), two cougars (Felis concolor, one male and one female), one bobcat (Felis rufus, male), and one cheetah (Acinonyx jubatus, female).
  • Neoplasia rate at necropsy was 51% (24/47), and overall incidence of felid neoplasia during the study period was 25% (26/103).
  • Neoplasia was identified as the cause of death or reason for euthanasia in 28% (13/47) of those necropsied.
  • Neoplasms were observed in the integumentary-mammary (n=11), endocrine (n=10), reproductive (n=8), hematopoietic-lymphoreticular (n=5), digestive (n=3), and hepatobiliary (n=2) systems.
  • One neoplasm was unclassified by system.
  • Multiple neoplasms were observed in 11 animals.
  • Both benign and malignant neoplasms were observed in all systems except for the hematopoietic-lymphoreticular systems where all processes were malignant.
  • Of the endocrine neoplasms, those involving the thyroid and parathyroid glands predominated (n=8) over other endocrine organs and included adenomas and carcinomas.
  • In the integumentary system, 63% (7/11) of neoplasms involved the mammary gland, with mammary carcinoma representing 83% (6/7) of the neoplasms.
  • The rates of neoplasia at this institution, during the given time period, appears to be greater than rates found in the one other published survey of captive felids.
  • [MeSH-major] Felidae. Neoplasms / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110704.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Waldmann J, Fendrich V, Holler J, Buchholz M, Heinmöller E, Langer P, Ramaswamy A, Samans B, Walz MK, Rothmund M, Bartsch DK, Slater EP: Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer; 2010 Sep;17(3):743-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray analysis reveals differential expression of benign and malignant pheochromocytoma.
  • The diagnosis of a malignant pheochromocytoma (PC) can only be established by the presence of distant metastases, but a subset of apparently benign PCs develop metastases.
  • We have employed a microarray analysis to identify a typical gene expression profile which distinguishes malignant from benign PC.
  • Total RNA was isolated from fresh-frozen tissue of five benign and five malignant PCs.
  • The analysis revealed a more than twofold difference in expression between benign and malignant PCs in 132 genes: 19 were up-regulated and 113 were down-regulated.
  • Comparative analysis by microarray of all ten PCs (benign/malignant) versus normal adrenal medulla revealed a more than twofold expression difference in 455/539 and 491/671 genes respectively.
  • Several of these genes are known to participate on adrenal tumorigenesis, potential tumor suppressor genes, and oncogenes.
  • Comprehensive gene expression analysis of malignant and benign PCs revealed different gene profiles, which could be used to discriminate between malignant and benign PCs.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Medulla / metabolism. Biomarkers, Tumor / metabolism. Gene Expression Profiling. Pheochromocytoma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Young Adult


82. d'Assignies G, Couvelard A, Bahrami S, Vullierme MP, Hammel P, Hentic O, Sauvanet A, Bedossa P, Ruszniewski P, Vilgrain V: Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology; 2009 Feb;250(2):407-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.
  • PURPOSE: To prospectively correlate multidetector computed tomographic (CT) perfusion measurement of pancreatic endocrine tumors with tumor microvascular density (MVD) assessed by using histologic techniques and to determine whether perfusion CT parameters differ between tumor grades.
  • Thirty-six patients (15 men, 21 women; mean age, 53 years; range, 18-78 years) with resectable pancreatic endocrine tumors underwent presurgical dynamic perfusion CT.
  • Multidetector CT perfusion data were analyzed to calculate tumor and normal pancreatic blood flow, blood volume, mean transit time, and permeability-surface area product.
  • Multidetector CT perfusion parameters were compared with intratumoral MVD by using the Spearman correlation coefficient and with World Health Organization (WHO) classification, tumor size, tumor proliferation index, hormonal profile, and presence of metastases by using Mann-Whitney tests.
  • RESULTS: High correlation (r = 0.620, P < .001) was observed between tumor blood flow and intratumoral MVD.
  • Blood flow was significantly higher (P = .02) in the group of benign tumors (WHO 1) than in the groups of tumors of indeterminate prognosis (WHO 2) or well-differentiated carcinomas (WHO 3).
  • CONCLUSION: Perfusion CT is feasible in patients with pancreatic endocrine tumors and reflects MVD.
  • [MeSH-major] Neovascularization, Pathologic / radiography. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiographic Image Interpretation, Computer-Assisted. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095784.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Chirletti P, Peparini N, Caronna R, Fanello G, Delogu G, Meniconi RL: Roux-en-Y end-to-end and end-to-side double pancreaticojejunostomy: application of the reconstructive method of the Beger procedure to central pancreatectomy. Langenbecks Arch Surg; 2010 Jan;395(1):89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Roux-en-Y end-to-end and end-to-side double pancreaticojejunostomy: application of the reconstructive method of the Beger procedure to central pancreatectomy.
  • PURPOSES: Central pancreatectomy is indicated for treatment of traumatic lesions and benign or low-grade tumors of the pancreatic neck and proximal body.
  • METHODS: Reconstruction by Roux-en-Y double pancreaticojejunostomy after central pancreatectomy was done in a 71-year-old female suffering from insulinoma of the proximal pancreatic body.
  • No alteration of pancreatic endocrine and exocrine function occurred at 22-month follow-up.
  • [MeSH-major] Anastomosis, Roux-en-Y / methods. Insulinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Pancreaticojejunostomy / methods
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Length of Stay. Neoplasm Staging. Reconstructive Surgical Procedures / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):266-71 [15864637.001]
  • [Cites] Ann Chir. 2002 Jan;127(1):48-54 [11833306.001]
  • [Cites] Pancreas. 1987;2(6):701-7 [3438308.001]
  • [Cites] J Surg Oncol. 2009 Sep 1;100(3):273-6 [19267362.001]
  • [Cites] Ann Surg. 1994 Oct;220(4):492-504; discussion 504-7 [7524454.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):871-6 [15194067.001]
  • [Cites] Surgery. 2002 Nov;132(5):836-43 [12464868.001]
  • [Cites] Arch Surg. 2008 Feb;143(2):175-80; discussion 180-1 [18283143.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):573-82 [17414606.001]
  • [Cites] Surg Gynecol Obstet. 1959 Oct;109:473-8 [14416087.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):1090-7 [15702531.001]
  • [Cites] Surgery. 2007 Sep;142(3):405-9 [17723894.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):804-12 [16769536.001]
  • [Cites] J Gastrointest Surg. 2009 Sep;13(9):1659-65 [19488821.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2096-103 [18521682.001]
  • [Cites] Br J Surg. 2005 May;92(5):539-46 [15852419.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(4):283-5 [16133693.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):69-76 [17592293.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(4):373-6 [18670837.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1264-78; discussion 1278-9 [17114013.001]
  • [Cites] Mem Acad Chir (Paris). 1957 Nov 13-20;83(27-28):869-71 [13503655.001]
  • [Cites] Arch Surg. 2006 Mar;141(3):293-9 [16549696.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):364-76 [17458612.001]
  • [Cites] Chirurgie. 1998 Sep;123(4):363-7 [9828510.001]
  • [Cites] Arch Surg. 1998 Mar;133(3):327-31 [9517749.001]
  • [Cites] Hepatogastroenterology. 2008 Jul-Aug;55(85):1478-9 [18795716.001]
  • [Cites] Am J Surg. 2008 Sep;196(3):364-72 [18513691.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2009;16(3):399-400; author reply 401 [19240968.001]
  • [Cites] Dig Surg. 2001;18(1):21-5 [11244255.001]
  • [Cites] Surgery. 1985 Apr;97(4):467-73 [3983823.001]
  • [Cites] Surgery. 2005 Jul;138(1):8-13 [16003309.001]
  • [Cites] ANZ J Surg. 2006 Nov;76(11):987-95 [17054548.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(4):377-83 [18670838.001]
  • (PMID = 19707783.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Christein JD, Smoot RL, Farnell MB: Central pancreatectomy: a technique for the resection of pancreatic neck lesions. Arch Surg; 2006 Mar;141(3):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although historically used for traumatic pancreatic transection and chronic pancreatitis, it currently is reserved for selective management of pancreatic neck lesions that are benign or have low malignant potential.
  • Our objectives were to describe the technique and determine the safety and effectiveness of central pancreatectomy in the excision of benign or low-malignant potential lesions of the pancreatic neck.
  • On follow-up, long-term endocrine and exocrine function were determined based on laboratory values and patient history.
  • Mean tumor size was 2.8 cm and mean operative time was 4.8 hours with a mean blood loss of 381 mL.
  • CONCLUSIONS: Central pancreatectomy may preserve endocrine and exocrine function.
  • The precise role of central pancreatectomy in the management of benign or low-malignant potential lesions of the neck of the pancreas remains in evolution.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenoma, Islet Cell / radiography. Adenoma, Islet Cell / surgery. Cystadenoma, Serous / radiography. Cystadenoma, Serous / surgery. Female. Humans. Liposarcoma / surgery. Male. Mesenteric Veins / surgery. Middle Aged. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549696.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Delle Fave G, Capurso G, Milione M, Panzuto F: Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):659-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumours of the stomach.
  • Gastric endocrine tumours (gastric carcinoids) usually grow from enterochromaffin-like (ECL) cells.
  • Three types of tumour may be distinguished on the basis of the background gastric pathology: type I, which develops in atrophic body gastritis (ABG); type II, which is associated with multiple endocrine neoplasia and Zollinger-Ellison syndrome; and the sporadic type III, which is not associated with any background pathology.
  • In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases.
  • [MeSH-major] Carcinoid Tumor / epidemiology. Carcinoid Tumor / pathology. Neoplasm Invasiveness / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Gastrectomy / methods. Gastric Mucosa / pathology. Gastroscopy / methods. Humans. Immunohistochemistry. Incidence. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome. Zollinger-Ellison Syndrome / epidemiology. Zollinger-Ellison Syndrome / pathology. Zollinger-Ellison Syndrome / surgery


86. Mihai R, Parker AJ, Roskell D, Sadler GP: One in four patients with follicular thyroid cytology (THY3) has a thyroid carcinoma. Thyroid; 2009 Jan;19(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytological criteria for benign (THY2) and malignant (THY5) aspirates are well established and reliable.
  • When cytology suggests a follicular neoplasm (THY3), only formal histological assessment can differentiate between benign and malignant lesions.
  • The objective of this study was to determine the factors predictive of malignancy in thyroid nodules when cytological assessment is restricted to euthyroid patients living in an area without endemic goiter who undergo routine diagnostic lobectomy once the FNA raises the suspicion of a follicular neoplasm.
  • Benign tumors were found in 144 patients with follicular adenomas (n = 76), Hurthle cell adenomas (n = 33), multinodular goiter (n = 13), adenomatoid nodules (n = 15), colloid nodules (n = 4), and thyroiditis (n = 3).
  • CONCLUSION: One in four patients with cytological features of a follicular neoplasm has a thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Thyroid Nodule / diagnosis. Thyroid Nodule / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cohort Studies. Diagnosis, Differential. Female. Humans. Incidence. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Risk Factors. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976164.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Mohan H, Garg S, Punia RP, Dalal A: Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature. JOP; 2007;8(4):453-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined serous cystadenoma and pancreatic endocrine neoplasm. A case report with a brief review of the literature.
  • CONTEXT: The presence of a combined serous cystadenoma and pancreatic endocrine neoplasm is a distinct clinicopathological entity rather than the incidental concurrence of two separate entities.
  • CASE REPORT: We report the case of a 52-year-old woman admitted to our hospital who had suffered from epigastric pain, nausea and vomiting for 4 months.
  • The diagnosis of combined microcystic adenoma and pancreatic endocrine neoplasm was made.
  • The coexistence of pancreatic endocrine neoplasms with potential malignant behavior may be overshadowed by obvious benign tumors such as a microcystic serous cystadenoma.
  • The malignant potential and prognostic features of this neoplasm require long-term follow-up and additional data from subsequent reports of such cases.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / complications. Cystadenoma, Serous / complications. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625299.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


88. Alexakis N, Neoptolemos JP: Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol; 2008;22(1):183-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic neuroendocrine tumours are rare tumours ( approximately 1/100,00 population/year) of which 60% are non-functioning.
  • In multiple endocrine neoplasia (MEN)1, pancreatic neuroendocrine tumours occur in 40-80% of patients and are mostly non-functioning tumours or gastrinomas.
  • Insulinomas are benign in approximately 90%, solitary in 95% of sporadic cases whilst multiple in 90% of MEN1 patients.
  • In contrast approximately 50% gastrinomas and the majority of non-functioning pancreatic neuroendocrine tumours are malignant.
  • Non-functioning tumours should also be resected if sporadic and if >2 cm in MEN1 or if >2-3 cm in VHL.
  • [MeSH-major] Neuroendocrine Tumors. Pancreatic Neoplasms
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Antineoplastic Agents / therapeutic use. Hormones / therapeutic use. Humans. Liver Neoplasms / secondary. Neoplasm Staging. Positron-Emission Tomography / methods. Receptors, Somatostatin / therapeutic use. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Tomography, X-Ray Computed / methods. von Hippel-Lindau Disease / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206821.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hormones; 0 / Receptors, Somatostatin; 35MRW7B4AD / 3-Iodobenzylguanidine; 51110-01-1 / Somatostatin
  • [Number-of-references] 125
  •  go-up   go-down


89. Adam N, Lim SS, Ananda V, Chan SP: VIPoma syndrome: challenges in management. Singapore Med J; 2010 Jul;51(7):e129-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vasoactive intestinal peptide-producing tumour (VIPoma) or Verner-Morrison syndrome is a very rare neuroendocrine tumour.
  • Diagnosis is characteristically delayed.
  • It may be curative in forty percent of patients with benign and non-metastatic disease.
  • Somatostatin analogues improve hormone-mediated symptoms, reduce tumour bulk and prevent local and systemic effects.
  • We present a female patient with VIPoma syndrome, which had metastasised to the liver at diagnosis.
  • [MeSH-major] Liver Neoplasms / secondary. Palliative Care. Pancreatic Neoplasms / pathology. Vipoma / secondary
  • [MeSH-minor] Catheter Ablation / methods. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Octreotide / therapeutic use. Time Factors. Treatment Outcome


90. Kyrönlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefström J, Wilson DB, Anttonen M, Heikinheimo M: GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer; 2010 Sep;17(3):709-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent cytokine that induces apoptosis in a variety of malignancies without toxic effects on benign cells.
  • [MeSH-major] Apoptosis. GATA4 Transcription Factor / metabolism. Granulosa Cell Tumor / metabolism. Granulosa Cell Tumor / pathology. Neoplasm Recurrence, Local / metabolism. TNF-Related Apoptosis-Inducing Ligand / metabolism
  • [MeSH-minor] Cell Line, Tumor. Female. Granulosa Cells / metabolism. Granulosa Cells / pathology. Humans. Immunoenzyme Techniques. Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20554787.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA4 Transcription Factor; 0 / GATA4 protein, human; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human
  •  go-up   go-down


91. Bargren AE, Meyer-Rochow GY, Sywak MS, Delbridge LW, Chen H, Sidhu SB: Diagnostic utility of fine-needle aspiration cytology in pediatric differentiated thyroid cancer. World J Surg; 2010 Jun;34(6):1254-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was designed to determine the ability of fine-needle aspiration cytology (FNA) to diagnose accurately and facilitate management of thyroid neoplasms in pediatric patients.
  • FNA sensitivity for diagnosing papillary thyroid cancer (PC) and follicular neoplasm (FN) was investigated.
  • Among the PCs patients, the FNA results were as follows: 1 (4%) nondiagnostic, 6 (22%) atypical, 2 (7%) benign, and 18 (67%) malignant lesions.
  • The sensitivity of a malignant FNA was 90% for diagnosing a PC.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2006 Jan-Feb;12(1):63-102 [16596732.001]
  • [Cites] Thyroid. 1998 Apr;8(4):283-9 [9588492.001]
  • [Cites] Semin Nucl Med. 2007 Sep;37(5):340-56 [17707241.001]
  • [Cites] Surgery. 2006 Dec;140(6):1000-5; discussion 1005-7 [17188149.001]
  • [Cites] Cancer. 1997 Dec 1;80(11):2156-62 [9392339.001]
  • [Cites] Arch Dis Child. 2001 Oct;85(4):313-7 [11567941.001]
  • [Cites] Endocr Pract. 2003 Mar-Apr;9(2):128-36 [12917075.001]
  • [Cites] Semin Pediatr Surg. 2001 Aug;10(3):119-26 [11481648.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):761-8 [12956795.001]
  • [Cites] Head Neck Surg. 1985 Nov-Dec;8(2):100-14 [3908407.001]
  • [Cites] Vopr Onkol. 2003;49(3):366-9 [12926223.001]
  • [Cites] Am Surg. 1993 Jul;59(7):415-9 [8323073.001]
  • [Cites] South Med J. 1997 Dec;90(12):1183-6 [9404902.001]
  • [Cites] Horm Res. 1999;52(1):15-8 [10640894.001]
  • [Cites] J Pediatr Endocrinol Metab. 1997 Nov-Dec;10(6):561-8 [9467125.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):533-41 [9563542.001]
  • [Cites] Ann Intern Med. 1997 Feb 1;126(3):226-31 [9027275.001]
  • [Cites] Cancer. 2001 Aug 25;93(4):263-8 [11507700.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):525-32 [16552205.001]
  • [Cites] Cancer. 2007 Oct 25;111(5):306-15 [17680588.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 May;124(5):531-6 [11337658.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] J Pediatr Surg. 2000 Jun;35(6):955-9; discussion 960 [10873043.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):59-65 [18043257.001]
  • [Cites] J Clin Endocrinol Metab. 1955 Oct;15(10):1270-80 [13263417.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):24-8 [9920057.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):724-9 [12209714.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Sep;34(3):725-44, x [16085168.001]
  • [Cites] Thyroid. 1998 Jan;8(1):15-21 [9492148.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):406-16 [16773630.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10 ):4644-8 [11600519.001]
  • [Cites] Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi [17673125.001]
  • [Cites] Can J Surg. 2005 Feb;48(1):12-8 [15757031.001]
  • [Cites] Endocrinol Metab Clin North Am. 2001 Jun;30(2):361-400 [11444167.001]
  • [Cites] Yonsei Med J. 2003 Aug 30;44(4):635-40 [12950119.001]
  • [Cites] J Pediatr Surg. 2004 Oct;39(10):1500-5 [15486894.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):92-100 [11258788.001]
  • [Cites] J Pediatr Surg. 2005 Nov;40(11):1696-700 [16291154.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4924-7 [12414851.001]
  • [Cites] Diagn Cytopathol. 2006 Feb;34(2):101-5 [16514673.001]
  • [Cites] Endocr Pract. 2006 Nov-Dec;12(6):609-14 [17229656.001]
  • [Cites] Endokrynol Pol. 2006 Jul-Aug;57(4):356-61 [17006836.001]
  • [Cites] Pediatrics. 1995 Jan;95(1):46-9 [7770308.001]
  • [Cites] Hormones (Athens). 2007 Oct-Dec;6(4):269-78 [18055418.001]
  • [Cites] J Pediatr Surg. 1998 Aug;33(8):1302-5 [9722010.001]
  • [Cites] Endocrinol Metab Clin North Am. 1997 Dec;26(4):777-800 [9429860.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):879-88 [17536106.001]
  • [Cites] Tumori. 2005 Jul-Aug;91(4):355-7 [16277104.001]
  • [Cites] Diagn Cytopathol. 2005 Apr;32(4):189-92 [15754376.001]
  • [Cites] Ann Endocrinol (Paris). 2007 Jun;68(2-3):120-8 [17582381.001]
  • [Cites] Endocr Pract. 1995 Jan-Feb;1(1):9-13 [15251608.001]
  • (PMID = 20091309.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Imachi H, Murao K, Yoshimoto T, Sugimoto M, Kakehi Y, Hayashi T, Kushida Y, Haba R, Tahara R, Ishida T: Idiopathic unilateral adrenal hemorrhage in an elderly patient. Endocrine; 2010 Apr;37(2):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was admitted to our hospital for the evaluation of a right adrenal tumor (size, 10 × 9 cm²).
  • The final pathological diagnosis was simply idiopathic adrenal hematoma.
  • It is important to distinguish this benign lesion from a neoplasm and to consider idiopathic AH in an adrenal tumor during differential diagnosis in elderly patients who have not received anticoagulation therapy or suffered from trauma.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnostic imaging. Hematoma / diagnostic imaging. Hemorrhage / diagnostic imaging. Hypertension / diagnostic imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging


93. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, Hoffmann I, Aydin F, Knoefel WT, Stoecklein NH: Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol; 2010 Feb;162(2):391-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: EpCAM (CD326) is overexpressed in progenitor cells of endocrine pancreatic islands of Langerhans during fetal development and was suggested to act as a morphoregulatory molecule in pancreatic island ontogeny.
  • We tested whether EpCAM overexpression is reactivated in insulinomas, endocrine tumors arising in the pancreas.
  • DESIGN/METHOD: We used monoclonal anti-EpCAM antibody Ber-Ep4 for immunohistochemistry on formalin-fixed and paraffin-embedded tumor material.
  • We analyzed 53 insulinomas: 40 benign (disease stage<IIa) and 13 malignant tumors (disease stage IIIb/IV).
  • Disease stage disposition followed new TNM classification of the European Neuroendocrine Tumor Society (ENETS) for foregut neuroendocrine tumors (2006).
  • RESULTS: In 38% of the benign insulinomas (disease stage<IIa), we found strong (3+) EpCAM expression.
  • CONCLUSION: This first EpCAM expression study in benign/malignant insulinomas indicates that strong EpCAM expression could help to identify patients at risk for malignant disease and might be used as a therapeutic target for antibody-based therapies in patients with metastatic insulinoma.

  • Genetic Alliance. consumer health - Insulinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20097833.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / RNA, Messenger
  •  go-up   go-down


94. Mazzaferri EL: Management of low-risk differentiated thyroid cancer. Endocr Pract; 2007 Sep;13(5):498-512
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To summarize the definitions of and management recommendations for low-risk thyroid cancer made by the American and European Thyroid Associations and synthesize this information with the recent literature, including systematic evaluations of tumor staging systems guiding therapy.
  • Cancer-related mortality rates are usually less than 1%, but are as high as 2% in some reports.
  • Tumor staging systems are too inaccurate to guide therapy.
  • Preoperatively diagnosed PTMC should be treated with total or near-total thyroidectomy, regardless of tumor size.
  • For very low-risk patients with unifocal PTMC smaller than 1 cm that is removed by chance during surgery to treat benign thyroid disease, lobectomy alone without 131I therapy may be sufficient therapy if there are no concerning histologic features and no tumor extension beyond the thyroid, metastases, history of head and neck irradiation, or positive family history--any of which requires total or near-total thyroidectomy and remnant ablation with 30 mCi.
  • [MeSH-major] Iodine Radioisotopes / therapeutic use. Practice Guidelines as Topic. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / surgery. Thyroidectomy
  • [MeSH-minor] Cell Differentiation. Combined Modality Therapy. Humans. Incidence. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17872353.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Number-of-references] 95
  •  go-up   go-down


95. Hofer MD, Chang MC, Hirko KA, Rubin MA, Nosé V: Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Mod Pathol; 2009 Jul;22(7):933-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors.
  • Pancreatic endocrine tumors are rare tumors with unpredictable clinical behavior.
  • No histological features or immunohistochemical markers reliably predict malignant progression and the molecular basis of progression of pancreatic endocrine tumors remains unknown.
  • The metastasis-associated gene 1 is thought to play a role in transcription repression and estrogen receptor interaction and is overexpressed in several human cancers, including endocrine neoplasms.
  • The purpose of this study was to analyze the expression of metastasis-associated gene 1 in pancreatic endocrine tumors for its possible role in malignant progression.
  • Twenty-seven pancreatic endocrine tumors were identified from our archive.
  • The clinical follow-up data were examined and tumors were classified according to the 2004 World Health Organization criteria as benign behavior (WHO 1.1), uncertain behavior (WHO 1.2), well-differentiated endocrine carcinoma (WHO 2), and poorly differentiated endocrine carcinoma (WHO 3).
  • Metastasis-associated gene 1 expression was significantly higher in malignant tumors (n=17) with a mean staining intensity of 3.8 compared with 2.9 in benign tumors (n=10, P=0.046).
  • The expression levels were significantly associated with WHO class (P=0.028), as well as size of tumor (P=0.029), and mitotic rate (P=0.035).
  • We show that metastasis-associated gene 1 expression is significantly associated with malignant behavior in pancreatic endocrine tumors.
  • This may suggest a potential role for metastasis-associated gene 1 in the malignant progression and metastasis and its use as biomarker for malignant pancreatic endocrine tumors.
  • [MeSH-major] Adenoma, Islet Cell / enzymology. Carcinoma, Islet Cell / enzymology. Histone Deacetylases / metabolism. Islets of Langerhans / enzymology. Pancreatic Neoplasms / enzymology. Repressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377441.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


96. Fujarewicz K, Jarzab M, Eszlinger M, Krohn K, Paschke R, Oczko-Wojciechowska M, Wiench M, Kukulska A, Jarzab B, Swierniak A: A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer; 2007 Sep;14(3):809-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.
  • We also assessed the accuracy of benign/malignant classification, based on gene expression profiling, for PTC.
  • We analyzed a 180-array dataset (90 HG-U95A and 90 HG-U133A oligonucleotide arrays), which included a collection of 57 PTCs, 61 benign thyroid tumors, and 62 apparently normal tissues.
  • The accuracy of PTC diagnosis was 98.5% for a 20-gene classifier, its 95% confidence interval (CI) was 95.9-100%, with the lower limit of CI exceeding 95% already for five genes.
  • [MeSH-major] Automatic Data Processing / instrumentation. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Molecular Diagnostic Techniques / methods. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2000 Nov;53(5):635-44 [11106926.001]
  • [Cites] Thyroid. 2001 Jan;11(1):41-6 [11272096.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3640-6 [11325833.001]
  • [Cites] J Pathol. 2001 May;194(1):4-8 [11329134.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4583-90 [11389094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8961-5 [11470909.001]
  • [Cites] Thyroid. 2001 Aug;11(8):783-7 [11525273.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):875-80 [11556840.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4834-42 [11600550.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):175-83 [11786411.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):171-8 [15308542.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1037-46 [15650356.001]
  • [Cites] Radiat Res. 2005 Feb;163(2):172-82 [15658893.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] Thyroid. 2005 Mar;15(3):210-21 [15785240.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2314-20 [15623817.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):1921-4 [15687333.001]
  • [Cites] Bioinformatics. 2005 Apr 15;21(8):1509-15 [15572470.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1545-52 [15812549.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):906-13 [15854029.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2512-21 [15713710.001]
  • [Cites] Cancer Lett. 2005 Jun 28;224(2):289-301 [15914279.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):291-303 [15947104.001]
  • [Cites] Surgery. 1999 Dec;126(6):1200-4 [10598208.001]
  • [Cites] Endocrinology. 2000 Apr;141(4):1403-13 [10746644.001]
  • [Cites] Genomics. 2002 Jan;79(1):24-30 [11827454.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):912-23 [11981027.001]
  • [Cites] Oncogene. 2002 May 2;21(19):2971-80 [12082527.001]
  • [Cites] Endocr J. 2002 Aug;49(4):511-6 [12402984.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):260-9 [12519863.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Cytopathology. 2003 Feb;14(1):27-31 [12588307.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):6160-7 [12456677.001]
  • [Cites] Biochemistry. 2003 Apr 22;42(15):4569-77 [12693954.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2864-71 [12782592.001]
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):871-5 [12820316.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6784-90 [14583474.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):201-9 [14643421.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8500-6 [14679016.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):272-80 [14715861.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):795-804 [14737114.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1391-7 [14551144.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):703-6 [15266330.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):5397-405 [15271884.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1764-71 [15496625.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):654-8 [2479256.001]
  • [Cites] Oncogene. 1995 Jan 5;10(1):61-8 [7824279.001]
  • [Cites] J Biol Chem. 1995 Jul 21;270(29):17594-601 [7615566.001]
  • [Cites] J Cell Sci. 1996 Jan;109 ( Pt 1):191-7 [8834803.001]
  • [Cites] Genomics. 1996 Dec 15;38(3):273-6 [8975702.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1638-41 [9141564.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2322-8 [9215314.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):157-64 [9435434.001]
  • [Cites] Eur J Pharmacol. 1998 Jan 12;341(2-3):289-97 [9543251.001]
  • [Cites] Biochem Biophys Res Commun. 1998 May 29;246(3):888-94 [9618307.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):221-4 [9683297.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2817-23 [9709953.001]
  • [Cites] Genomics. 1998 Aug 1;51(3):445-51 [9721215.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11742-50 [10206990.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):956-62 [10362145.001]
  • [Cites] Mol Cell Endocrinol. 1999 May 25;151(1-2):103-19 [10411325.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3228-34 [10487692.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4542-5 [10493503.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6146-54 [15579771.001]
  • [Cites] Eur J Histochem. 2004 Jul-Sep;48(3):253-9 [15590415.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):282-6 [15627060.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2216-24 [15956966.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4155-61 [15806164.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2349-57 [15890670.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6646-56 [16007166.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):694-702 [16271081.001]
  • [Cites] Thyroid. 2005 Oct;15(10):1137-46 [16279847.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):81-9 [16391220.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):262-9 [16249278.001]
  • [Cites] Acta Chir Belg. 2005 Nov-Dec;105(6):644-8 [16438077.001]
  • [Cites] J Surg Res. 2006 Mar;131(1):15-25 [16256137.001]
  • [Cites] Am J Clin Pathol. 2006 Mar;125(3):399-406 [16613343.001]
  • [Cites] Biochimie. 2006 Mar-Apr;88(3-4):387-97 [16480812.001]
  • [Cites] BMC Bioinformatics. 2006;7:197 [16606446.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1934-42 [16407496.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2592-7 [16688775.001]
  • [Cites] Thyroid. 2006 Jul;16(7):633-42 [16889486.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):472-3 [16957755.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:12-7 [17091451.001]
  • [Cites] Placenta. 2007 Feb-Mar;28(2-3):77-84 [16584773.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):374-80 [14960464.001]
  • [Cites] Thyroid. 2004 Mar;14(3):169-75 [15072698.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1600-5 [15083192.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):547-56 [15080786.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3780-9 [15172984.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 28;1689(2):134-41 [15196594.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Histopathology. 2004 Aug;45(2):103-18 [15279628.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):1011-20 [15299084.001]
  • (PMID = 17914110.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2216417
  •  go-up   go-down


97. Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, Chen H: Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol; 2008 Oct;15(10):2842-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.
  • BACKGROUND: Hürthle cell neoplasms (HCNs) are rare tumors of the thyroid gland.
  • Medical records of 55 consecutive patients who underwent thyroid resections for the preoperative diagnosis of HCN were reviewed.
  • All HCNs less than 2 cm in diameter were benign.
  • One patient with HCC had recurrence of the disease, but there were no disease-related deaths.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665423.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / T35 DK062709
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS778770; NLM/ PMC4852735
  •  go-up   go-down


98. Bordi C, D'Adda T, Azzoni C, Pizzi S, Bottarelli L, Mormandi F, Antonetti T, Luong TV, Rindi G: Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol; 2006;17(2):119-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for malignancy in gastrointestinal endocrine tumors.
  • In contrast with the large amount of data generated from endocrine tumors of the pancreas, sparse and mostly unconfirmed data are available on the criteria for the assessment of malignancy risk and patient outcome in endocrine tumors of the gastrointestinal tract.
  • In these conditions the 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded as useful for clinical purposes, providing the basis for proper management of the patients and for the design of treatment protocols.
  • The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate.
  • (1) well-differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior;.
  • (2) well-differentiated endocrine carcinomas, low grade; and (3) poorly differentiated endocrine carcinomas, high grade.
  • In this review the differential tumor characteristics between the different categories are summarized.
  • Moreover, the relevance of additional features with respect to tumor prognostication, chiefly the Ki-67 proliferation index and malignancy-associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and of midgut origin.
  • [MeSH-major] Endocrine Gland Neoplasms / classification. Endocrine Gland Neoplasms / diagnosis. Gastrointestinal Neoplasms / classification. Gastrointestinal Neoplasms / diagnosis. Neoplasm Invasiveness / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Ki-67 Antigen. Mitotic Index. Prognosis. World Health Organization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] Histopathology. 2004 Oct;45(4):384-92 [15469477.001]
  • [Cites] World J Surg. 1998 Mar;22(3):309-18 [9494425.001]
  • [Cites] Q J Nucl Med. 2000 Mar;44(1):3-12 [10932597.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1903-11 [11395364.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1787-94 [10595906.001]
  • [Cites] Tumour Biol. 1992;13(1-2):27-35 [1317054.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1094-101 [11679944.001]
  • [Cites] J Pathol. 2002 Apr;196(4):401-7 [11920735.001]
  • [Cites] Yale J Biol Med. 1998 May-Aug;71(3-4):273-84 [10461358.001]
  • [Cites] Cancer. 1971 Oct;28(4):990-8 [4106849.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Virchows Arch. 1996 Dec;429(6):323-33 [8982376.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Dec;32(4):364-72 [11746977.001]
  • [Cites] Hum Pathol. 1988 May;19(5):580-5 [2453443.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1803-8 [11337378.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):258-64 [10502325.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):706-11 [14608896.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1273-82 [12973852.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1145-53 [15316313.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(5):387-98 [2845642.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1765-75 [15755998.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):311-5 [9927038.001]
  • [Cites] J Pathol. 1998 Sep;186(1):41-50 [9875139.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):532-42 [10029611.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:1-12 [15153415.001]
  • [Cites] Am J Pathol. 1989 Dec;135(6):1065-72 [2480712.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):233-45 [9665484.001]
  • [Cites] J Pathol. 1998 Aug;185(4):389-93 [9828837.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):472-8 [11257621.001]
  • [Cites] Cancer. 1983 Jan 15;51(2):277-82 [6821817.001]
  • [Cites] Am J Surg Pathol. 1995;19 Suppl 1:S8-19 [7762739.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;419(6):463-8 [1750193.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):532-8 [11920612.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):404-10 [9218518.001]
  • [Cites] J Pathol. 1999 Nov;189(3):394-401 [10547602.001]
  • [Cites] J Pathol. 2001 Aug;194(4):451-8 [11523053.001]
  • [Cites] J Pathol. 2005 Aug;206(4):409-16 [15887288.001]
  • [Cites] Am J Clin Pathol. 1990 Feb;93(2):273-6 [1689098.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):437-50 [14713256.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1448-53 [9326914.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Sep;1(3):323-33 [11901838.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):947-57 [14871972.001]
  • (PMID = 17159244.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  • [Number-of-references] 51
  •  go-up   go-down


99. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A: Prognosis of patients with benign thyroid diseases accompanied by incidental papillary carcinoma undetectable on preoperative imaging tests. World J Surg; 2007 Aug;31(8):1672-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of patients with benign thyroid diseases accompanied by incidental papillary carcinoma undetectable on preoperative imaging tests.
  • BACKGROUND: Despite the recent wide availability of ultrasonography and fine-needle aspiration biopsy, endocrine surgeons often encounter incidental papillary carcinoma (IPC), that is a papillary carcinoma that had gone undetected by preoperative imaging studies but was identified by pathological examination of surgical specimens resected for benign thyroid diseases.
  • METHODS: The present study was developed to investigate the prognoses of 317 patients who underwent surgery for benign diseases involving IPC in comparison with the prognoses of 1,674 patients with clinically apparent papillary carcinoma detected preoperatively and diagnosed.
  • RESULTS: None of the patients underwent further surgery such as completion total thyroidectomy and node dissection immediately after the diagnosis of IPC.
  • CONCLUSIONS: Because IPC is associated with good prognosis, further surgery, such as completion total thyroidectomy or lymph node dissection immediately after the diagnosis of IPC is not necessary.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Incidental Findings. Longitudinal Studies. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Analysis. Thyroid Diseases / surgery. Thyroidectomy. Treatment Outcome. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Clin Cancer Res. 2005 Jun;24(2):231-6 [16110756.001]
  • [Cites] Cancer. 1975 Sep;36(3):1095-9 [1182663.001]
  • [Cites] Eur J Surg. 1997 Apr;163(4):255-9 [9161822.001]
  • [Cites] Pathol Int. 2003 Sep;53(9):579-83 [14507313.001]
  • [Cites] World J Surg. 1991 Jul-Aug;15(4):511-5 [1891937.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1115-21 [15490053.001]
  • [Cites] Am Surg. 2005 Nov;71(11):911-3; discussion 913-5 [16372608.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Nov;63(5):577-81 [16268811.001]
  • [Cites] ANZ J Surg. 2006 Mar;76(3):123-6 [16626346.001]
  • [Cites] Surgery. 1992 Dec;112(6):1139-46; discussion 1146-7 [1455316.001]
  • [Cites] Endocr J. 1999 Feb;46(1):209-16 [10426589.001]
  • [Cites] Presse Med. 2000 Nov 25;29(36):1969-72 [11149075.001]
  • [Cites] Arch Surg. 2005 Oct;140(10 ):981-5 [16230549.001]
  • [Cites] Thyroid. 2003 Apr;13(4):381-7 [12804106.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):399-407 [12616125.001]
  • [Cites] Cancer. 2005 Aug 25;105(4):217-9 [15986395.001]
  • [Cites] Pathol Res Pract. 1992 Aug;188(6):747-50 [1437838.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Arch Pathol. 1971 Apr;91(4):334-9 [5549711.001]
  • [Cites] Am J Clin Pathol. 1988 Jul;90(1):72-6 [3389346.001]
  • (PMID = 17571205.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Jonmarker S, Glaessgen A, Culp WD, Pisa P, Lewensohn R, Ekman P, Valdman A, Egevad L: Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS; 2008 Jun;116(6):491-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue.
  • Pancreatic duodenal homeobox 1 (PDX-1), a Hox type transcription factor, is necessary for differentiation of exocrine and endocrine pancreas, and regulates insulin gene transcription.
  • We separately arrayed benign prostatic tissue, atrophy, high-grade prostatic intraepithelial neoplasia (HGPIN) and PCa from 40 men and also 17 lymph node metastases.
  • PDX-1 was overexpressed in cancer vs benign tissue (p<0.001), but also in atrophy and HGPIN vs cancer (p<0.001 and p=0.022, respectively).
  • Presence of PDX-1 protein in benign and malignant prostatic tissue was confirmed by Western blot.
  • [MeSH-major] Homeodomain Proteins / metabolism. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism. Trans-Activators / metabolism
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Metastasis. Tissue Array Analysis. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754323.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down






Advertisement